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Abstract 
Melanoma is often characterized by a constitutively active MAP kinase pathway. For 
inhibition of the aberrantly activated MAP kinase pathway targeted therapies with 
specific BRAF inhibitors are available that are very effective in the beginning but futile as 
soon as resistance occurs after a few months. Hence, a better understanding of the 
mechanisms mediating resistance is necessary to increase the success of the treatment. 
In this study I observed that SOX2 and CD24 were upregulated shortly after the BRAF 
inhibitor treatment was started. A similar upregulation was seen in melanoma-derived 
induced pluripotent cancer cells (iPCCs) which are resistant to targeted therapy. SOX2 
and CD24 are known to promote an undifferentiated and cancer stem cell-like 
phenotype associated with resistance. Therefore, I elucidated the role of SOX2 and 
CD24 in resistance to targeted therapy in more detail. I found that the upregulation of 
SOX2 and CD24 required activation of STAT3. The STAT3 activation was caused by 
soluble factors which were at least partially cleaved by sheddases. Moreover, I detected 
that SOX2 induced the expression of CD24 by binding to its promoter. Additionally, I 
found that the overexpression of SOX2 significantly increased the resistance towards 
BRAF inhibitors, while SOX2 knockdown rendered the cells more sensitivity towards 
treatment. CD24 overexpression could mimic the effect of SOX2 overexpression while 
CD24 knockdown in SOX2 overexpressing cells re-established the sensitivity towards 
BRAF inhibitors. Furthermore, the overexpression of CD24 or SOX2 induced Src and 
STAT3 activity. Importantly, the more resistant SOX2 or CD24 overexpressing cells 
were still sensitive to Src/STAT3 inhibition. In contrast, in acquired resistance neither 
SOX2 nor CD24 played a major role. Here, other molecules and pathways mediate the 
cells’ resistance to the treatment. Therefore, I suggest that the BRAF inhibitor induced 
activation of STAT3 and the resulting increased expression of SOX2 and CD24 work as 
an escape pathway to save some cancer cells from the BRAF inhibitor-induced cell 
death. In the long term these cells can then acquire other mechanisms to circumvent the 
BRAF inhibitor action and regrow. Thus, to prevent adaptive resistance it might be 
beneficial to combine Src/STAT3 inhibitors together with MAP kinase pathway inhibitors. 
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Zusammenfassung 
Im malignen Melanom ist meistens der MAP Kinase Signalweg unverhältnismäßig stark 
aktiviert. Daher wurden zur Melanomtherapie Moleküle entwickelt, die diesen Signalweg 
inhibieren, z.B. BRAF Inhibitoren. Diese sind zu Beginn sehr effektiv, aber da sich meist 
recht schnell eine Resistenz ausbildet, stellt diese Therapie einen Zeitgewinn, aber 
keine dauerhafte Lösung dar. Deshalb ist es wichtig, die Mechanismen der 
Resistenzbildung zu erforschen und somit den Erfolg dieser Form der Therapie zu 
erhöhen. 
In dieser Arbeit habe ich festgestellt, dass die SOX2 und CD24 Expression kurz nach 
der Behandlung von Melanomzellen mit BRAF Inhibitoren erhöht war. Eine ähnlich 
erhöhte Expression von SOX2 und CD24 konnte ich in induzierten, pluripotenten 
Krebszellen, die aus Melanomzellen gewonnen wurden, nachweisen. Deshalb habe ich 
die Rolle von SOX2 und CD24 in der Resistenzbildung gegen BRAF Inhibitoren genauer 
untersucht. Ich konnte feststellen, dass eine STAT3 Aktivierung für die durch BRAF 
Inhibitoren erhöhte Expression von SOX2 und CD24 notwendig ist. STAT3 wird durch 
Faktoren im Überstand aktiviert, welche nach der Behandlung mit BRAF Inhibitoren 
angereichert werden. Diese Faktoren werden zumindest teilweise von Sheddasen 
gespalten. Des Weiteren konnte ich zeigen, dass SOX2 direkt an den Promotor von 
CD24 bindet und somit für die erhöhte CD24 Expression verantwortlich ist. Außerdem 
konnte ich nachweisen, dass eine Überexpression von SOX2 zu einer signifikant 
erhöhten Resistenz gegen BRAF Inhibitoren führt, während SOX2 Knockdown die 
Zellen sensitiver gegenüber BRAF Inhibitoren macht. Eine CD24 Überexpression zeigt 
den gleichen Effekt wie eine SOX2 Überexpression, während CD24 Knockdown in den 
resistenteren SOX2 überexprimierenden Zellen zu einer Wiederherstellung der 
Sensitivität gegenüber dem BRAF Inhibitor führt. Des Weiteren führen sowohl SOX2 als 
auch CD24 Überexpression zur Aktivierung von Src und STAT3. Eine wichtige 
Beobachtung war, dass die resistenteren SOX2 oder CD24 überexprimierenden Zellen 
noch immer sensitiv gegenüber Src und STAT3 Inhibitoren waren. Im Gegensatz zur 
adaptiven Resistenz konnte ich zeigen, dass bei der erworbenen Resistenz weder 
SOX2 noch CD24 eine wichtige Rolle spielen. Dafür sind bei der erworben Resistenz 
andere Moleküle und Signalwege wichtig um den Effekten des Inhibitors zu entkommen. 
Zusammenfassung 
 
VI 
 
Meine Arbeit gibt daher einen Hinweis darauf, dass die durch den BRAF Inhibitor 
ausgelöste Aktivität von STAT3 und die damit einhergehende erhöhte Expression von 
SOX2 und CD24 eine Art Fluchtweg darstellen, um so einige Zellen vor dem durch den 
Inhibitor hervorgerufen Zelltod zu schützen. Diese Zellen können dann mit der Zeit 
andere Mechanismen erwerben, um dem BRAF Inhibitor zu entkommen und weiter zu 
wachsen. Aus diesen Gründen wäre es vorteilhaft, Src oder STAT3 Inhibitoren 
zusätzlich zu den Inhibitoren des MAP Kinase Signalwegs zu verabreichen, da so 
eventuell die adaptive Resistenz verhindert werden kann.  
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1 Introduction 
1.1 Melanoma 
Melanoma is a skin cancer which arises from transformed melanocytes. The malignant 
degeneration of melanocytes in the epidermis is the most frequent form of this disease 
and is called cutaneous melanoma. The other, non-cutaneous melanomas, can arise 
from the choroidal layer of the eye or the mucosal surfaces of the respiratory, 
gastrointestinal, and genitourinary tract (Tsao et al. 2012). Melanoma is one of the most 
aggressive types of skin cancer as it only represents 4 % of the dermatological cancer 
cases but leads to 80 % of deaths caused by skin cancer (Miller & Mihm 2013). 
Melanoma incidences increase in many parts of the world where light-skinned people 
live. Now, melanoma is one of the most frequent cancers in light-skinned people. One 
risk factor for developing melanoma is the exposure to ultraviolet (UV) light, which is part 
of the solar radiation, as this can cause genetic mutations in melanocytes (Gandini et al. 
2005; Rastrelli et al. 2014). The defensive mechanism to protect the skin from the UV 
damage is tanning. During tanning the melanocytes produce melanin which is 
transferred to keratinocytes and which absorbs and scatters the UV light (Miller & Mihm 
2013). People with darker skin have a better protection from UV light and therefore have 
a lower risk of developing cutaneous melanoma in comparison to light-skinned people 
(Fajuyigbe & Young 2016). Other melanoma risk factors are immunosuppression, i.e. 
after organ transplantation (Moloney et al. 2006), a high number of congenital 
melanocytic nevi (Ribeiro et al. 2016) or a melanoma family history (Read et al. 2015). 
1.1.1 Melanoma therapy 
The mutations causing melanoma are diverse and during melanoma pathogenesis the 
tumors develop into a quite heterogeneous cell population. For this reason, the 
treatment of melanoma differs according to criteria as stage and mutational status. In 
primary stage tumors surgical excision is still the first-line treatment. After excision the 
thickness of the tumor and the result of the lymph node biopsy direct the next step of 
treatment. Before the age of targeted therapy, the most commonly used therapy for 
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metastatic melanoma was chemotherapy with drugs such as dacarbazine and 
immunotherapy mostly with interleukin-2 (IL-2). These were either given separately or in 
combination (Bhatia et al. 2009). 
Nowadays, there are several therapeutic options for the treatment of patients with 
metastatic melanoma. These can be divided into two groups: the targeted therapies and 
the immune therapies.  
1.1.1.1 Targeted Therapy 
The most common mutation in melanoma is the BRAFV600E mutation leading to a 
constitutive activation of the mitogen-activated protein Kinase (MAPK) pathway (Figure 
1) which plays a major role in proliferation and survival of cells (Muñoz-Couselo et al. 
2015). Therefore, cells with this mutation have a dramatic growth increase. Melanoma 
cells with this mutation can be treated with the FDA approved BRAF inhibitors 
dabrafenib (GSK2118436) or vemurafenib (PLX4032) (Samatar & Poulikakos 2014). 
Unfortunately, BRAF inhibitors only increase the lifespan of patients about 6-7 months 
since resistance occurs after a short period of treatment (Klinac et al. 2013).  
Another possibility to target the MAPK pathway in patients with BRAF or NRAS mutation 
is to target MEK1/2 which is downstream of BRAF and NRAS. Trametinib 
(GSK1120212) which inhibits MEK1 and 2 and cobimetinib (GDC-0973, XL-518) which 
inhibits the catalytic activity of MEK1 were developed and approved by the FDA 
(Colombino et al. 2014), but also here resistance towards the inhibitor certainly occurs.  
More recently, the FDA approved the combination of vemurafenib and cobimetinib as 
well as the combination of dabrafenib and trametinib for the treatment of patients with a 
BRAFV600E mutation. These combination therapies result in a significantly longer survival 
than the monotherapy (Flaherty et al. 2012; Klinac et al. 2013; Long et al. 2017; Long et 
al. 2014). Furthermore, a second generation of vemurafenib (plx8394, plx7904) with less 
side effects and higher efficiency was developed (Zhang et al. 2015). Noteworthy, 
plx8394 is now in a clinical trial phase 1/2a with an estimated completion in the year 
2020 (https://clinicaltrials.gov/ct2/show/NCT02428712). 
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Figure 1: Normal vs oncogenic MAPK pathway. Mutation of BRAF leads to a constitutive activation of 
the MAPK pathway. No growth factors, which are usually essential for the activation of wild type BRAF, 
are needed anymore. BRAF mutation leads to an excessive cell proliferation and survival. This figure was 
adapted from Muñoz-Couselo et al. 2015. 
1.1.1.2 Immunotherapy 
As melanoma is a highly immunogenic tumor immunotherapy can be used to stimulate 
the immune system to attack the tumor. Formerly, for this purpose IL-2 or Interferon 
alpha (IFN-α) were utilized (Bhatia et al. 2009). But this approach had heavy side effects 
and was not as effective as the new immunotherapies which were developed after 
having a better understanding of the immune system. New immune checkpoint inhibitors 
developed in the last decade such as targeting cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) showed very promising 
results and are therefore used in the clinics. CTLA-4 is a molecule which downregulates 
the response of T-cells. Tumor cells escape from the immune system by expressing high 
amounts of CTLA-4 and thereby inhibiting T-cell activity. Ipilimumab is a monoclonal 
antibody that blocks CTLA-4 and hence leads to an increase in cytotoxic T-cell 
activation. These T-cells can then kill the tumor cells (Sanlorenzo et al. 2014).  
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PD-1 is a receptor on T-cells which is activated by PDL-1 and PDL-2 leading to an 
inhibition of cytotoxic T-cells. In a healthy system this is used to avoid autoimmunity 
while cancer cells use PDL-1 to inhibit the immune system. Nivolumab and 
pembrolizumab are monoclonal antibodies that target PD-1 and block it. Hence, this 
treatment leads to an increased immune response also against the tumor (Topalian et 
al. 2017; Sanlorenzo et al. 2014). 
1.1.2 Melanoma drug resistance 
Due to the development of a new generation of drugs targeting the MAPK pathway, the 
overall survival of metastatic melanoma patients increased significantly. But as 
described in 1.1.1.1 resistance towards targeted therapy limits its therapeutic efficacy. 
Resistance can be divided into intrinsic, adaptive and acquired resistance. Intrinsic 
resistance is already present before the administration of a targeted therapy compound 
and hence these patients do not respond to therapy at all (Spagnolo et al. 2015). 
Adaptive resistance occurs shortly after the application of the drug to the tumor cells 
while acquired resistance develops after continuous inhibitor treatment (Kugel & Aplin 
2014). 
1.1.2.1 Intrinsic resistance  
About 15 % of melanoma patients do not respond to BRAF inhibitor treatment due to 
intrinsic (primary) resistance (Spagnolo et al. 2015). The mechanisms of intrinsic 
resistance are highly studied. One know mechanism of resistance are mutations in 
RAC1, which plays an important role in cell proliferation and migration (Van Allen et al. 
2014). Furthermore, it was demonstrated that the secretion of HGF/cMET is involved in 
primary resistance. HGF can be secreted by the cancer cells leading to a paracrine 
activation of PI3K which then promotes tumor cell growth and thereby circumvents the 
growth inhibitory effect of BRAF inhibitors (Manzano et al. 2016). Furthermore, mutation 
in the cyclin-dependent kinase 4 (CDK4) or amplification of cyclin D1 which are both 
important regulators of cell proliferation promotes intrinsic resistance (Smalley et al. 
2008). Another mechanism is a loss of PTEN, a tumor suppressor and negative 
regulator of PI3K. It has been shown that patients with inactive PTEN are more resistant 
towards BRAF inhibitor treatment (Nathanson et al. 2013). Moreover, a loss of the tumor 
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suppressor NF1 causing an activation of RAS, PI3K and MAPK pathways has also been 
shown to play a role in primary resistance (Gibney & Smalley 2013).  
 1.1.2.2 Adaptive resistance  
Adaptive resistance occurs rather fast after the application of the drug and is a 
mechanism to compensate for the action of the targeted therapy. Therefore, the tumor 
cells escape the inhibitor-induced cell death and can establish acquired resistance 
mechanisms allowing regrowth of the tumor (Kugel & Aplin 2014). The different known 
mechanisms of adaptive resistance towards BRAF inhibitors are summarized by Kugel & 
Aplin (2014) as shown in Figure 2. One possibility to overcome the inhibitory effect of the 
drug is to reactivate ERK1/2. This happens by downregulating the expression of DUSP 
and SPRY. DUSPs usually dephosphorylate ERK and thereby inactivate ERK. Hence, 
the lower expression of DUSPs causes a longer activation time of ERK. SPRY inhibits 
the activation of NRAS and if this inhibitor is downregulated, EGFR can easier activate 
NRAS resulting in an increased MAPK pathway activation. Another possibility is that 
MAPK inhibition leads to an increased AKT activation by an increase in PDGFRβ and 
ErbB3. The influence of PDGFRβ in adaptive resistance was also shown by Sun et al. 
(2014). Furthermore, a metabolic switch from glycolysis to oxidative phosphorylation, 
which favors the survival of the cells, can be the consequence of BRAF inhibitor 
treatment. This is due to an inhibitor induced expression of PGC1α and JARID1B which 
both favor oxidative phosphorylation (Kugel & Aplin 2014).  
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Figure 2: Mechanisms of adaptive resistance. Left: Reactivation of ERK1/2 by decreased expression 
of DUSP (Dual-specificity phosphatase) due to BRAF inhibitor treatment. DUSP facilitates the 
dephosphorylation of ERK (inactivation of ERK). Also SPRY (Sprouty) expression is downregulated. 
SPRY is an inhibitor of MAPK pathway activation. Middle: BRAF inhibition causes an increased 
expression of ErbB3 and PDGFRβ. ErbB3 and PDGFRβ are important players in AKT activation. Right: 
BRAF inhibition induces a metabolic switch from glycolysis to oxidative phosphorylation which facilitates 
cell survival. The switch is due to a BRAF inhibitor-induced upregulation of PGC1α which in addition to 
JARID1B (lysine- specific demethylase 5B) boosts oxidative phosphorylation. This figure was modified 
from Kugel& Aplin 2014. 
1.1.2.3 Acquired resistance  
In contrast to adaptive resistance acquired resistance appears after a longer period of 
continues treatment with an inhibitor but once it is established it can lead to a rapid 
relapse (Kugel & Aplin 2014). There are different known mechanisms of acquired 
resistance which are summarized in Figure 3. One possibility to overcome targeted 
therapy and to acquire resistance is a mutation in MEK leading to a reactivation of the 
MAPK pathway (Emery et al. 2009). Another possibility is a mutation in NRAS. An 
activating mutation in NRAS promotes RAF dimerization and activation (Nazarian et al. 
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2010). Furthermore, an overexpression of COT kinase which is able to reactivate the 
MAPK pathway in a RAF-independent way is a mechanism providing acquired 
resistance (Johannessen et al. 2010). In addition, different splice variants of BRAF can 
lead to a reactivation of the pathway (Poulikakos et al. 2011) as well as an amplification 
of BRAF (Shi et al. 2012). Also receptor tyrosine kinases (RTKs) like EGFR can be 
upregulated an thereby reactivate the survival and proliferation pathway either by 
signaling via PI3K or via CRAF to ERK (Nazarian et al. 2010; Spagnolo et al. 2015). 
 
Figure 3: Mechanisms of acquired resistance. Resistance towards vemurafenib can result from MEK 
mutations, NRAS mutations, COT overexpression, BRAF amplification or splicing variants or receptor 
tyrosine kinase (RTK) upregulation. This figure was adapted from Kliniac et al. 2013. 
1.2 SOX2 
The SRY (sex determining region Y)-related HMG box (SOX) is named after the SRY, 
which is a critical gene for sex determination. As these proteins contain a high-mobility 
group (HMG) for DNA recognition and binding, all proteins with a similarity in the HMG 
domain of 50 % or higher are called SOX proteins. SOX2 has a molecular mass of 
around 35 kDa. It is located on chromosome 3q26.3-q27 and belongs together with 
SOX1 and SOX3 to the SOXB1 group within the SOX family. Within the SOXB1 group 
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there is a large homology and all proteins consist of an N-terminal domain, an HMG 
domain and a C-terminal domain (Figure 4A). The HMG domain is highly conserved 
between different species and the transactivation domain within the C-terminal domain 
binds to promotor sequences and thereby activates or represses transcription (Figure 
4B) (reviewed by Weina & Utikal, 2014). 
SOX2 plays an important role in lineage fate determination and in the maintenance of 
the stem cell status as well as in the development of the neuroectodermal lineage 
(Sarkar & Hochedlinger 2013; Adameyko et al. 2012). It is noteworthy that members of 
the SOX family have redundant function with respect to the maintenance of the stem cell 
phenotype of stem cells (i.e. SOX1, SOX2, SOX3 and SOX9) (Sarkar & Hochedlinger 
2013). Furthermore, SOX2 is a major transcription factor in reprogramming somatic cells 
into pluripotent stem cells (Takahashi & Yamanaka 2006). Since SOX2 is an important 
player its dysregulation has been linked to different diseases as well as cancer (Sarkar & 
Hochedlinger 2013; Weina & Utikal 2014). 
 
Figure 4: SOX2 structure and homology to members of the SOXB1 group. A: SOX2 belongs to the 
SOXB1 group of the SOX family together with SOX1 and SOX3. Each member of the family consists of an 
N-terminal domain, an HMG-domain and a C-terminal domain. B: The HMG domain is used for DNA 
recognition and binding and is conserved between different species. The transactivation domain can be 
used for promotor binding. This figure was modified from Weina & Utikal, 2014. 
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1.2.1 Role of SOX2 in cancer 
Cancer can be characterized by the hallmarks of cancer: sustained proliferation, evasion 
of growth suppression, increased invasion and metastasis formation, immortality, 
induced angiogenesis and resistance to cell death (Hanahan & Weinberg 2011). 
Increased SOX2 expression or amplification in tumor tissue compared to healthy tissue 
has been reported for a variety of different cancer types (Wuebben & Rizzino 2017). 
Additionally, SOX2 expression has been related to some cancer-specific characteristics 
in different types of cancers and it is well known that it can regulate and also is regulated 
by signaling pathways involved in cancer pathogenesis (Figure 5). It has been shown 
that SOX2 promotes cancer cell invasion, migration and metastases formation in 
melanoma and various other cancer types (Alonso et al. 2011; Han et al. 2012; Weina et 
al. 2016; Girouard et al. 2012; Sun et al. 2013). Furthermore, SOX2 can lead to 
increased proliferation (Santini et al. 2014) and can help to overcome apoptotic signals 
(Chen et al. 2014; Jia et al. 2011). Moreover, SOX2 is associated with poor prognosis in 
some cancer cell types (Sun et al. 2013; Wang et al. 2009) while in other cancer types it 
is even associated with a better prognosis (Wilbertz et al. 2011). Hence, the role of 
SOX2 can differ according to cancer type. Beyond that, SOX2 has been shown to play a 
role in determining the tumor-initiating cell population (putative cancer stem cells (CSC)) 
in a number of studies (Wuebben & Rizzino 2017; Weina & Utikal 2014; Santini et al. 
2014).   
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Figure 5: Role of SOX2 in cancer. SOX2 is involved in a lot of cellular processes. It is regulated by and 
regulates a variety of different signaling pathways. This figure was adapted from Weina and Utikal, 2014. 
 
1.2.2 SOX2 in therapy resistance 
A less differentiated cell state is associated with a higher resistance. As pluripotency 
markers like SOX2 typically promote an undifferentiated state of the cells, these 
pluripotency genes have been associated with resistance (Dogan et al. 2014). 
Furthermore, cancer cells that have been reprogrammed to pluripotency, the so-called 
induced pluripotent cancer cells (IPCCs), were shown to be more resistant towards 
targeted therapy (Bernhardt et al. 2017). A more undifferentiated state was also linked to 
adaptive resistance (Fallahi‐Sichani et al. 2017). In breast cancer it was demonstrated 
that SOX2 promotes resistance towards tamoxifen as silencing SOX2 restored 
tamoxifen sensitivity (Piva et al. 2014). In glioblastoma cells it was shown that SOX2 
was a necessary factor for the stem cell population and knockdown lead to reduced drug 
resistance (Song et al. 2016). There are a lot more studies addressing the role of SOX2 
in promoting therapy resistance (reviewed by Wuebben & Rizzino, 2017). One other 
possible mechanism by which SOX2 promotes drug resistance is linked to its ability of 
regulating ATP-binding cassette (ABC) transporters i.e. a study where decreased SOX2 
level reduces resistance by suppression of ABCG2 (S. H. Lee et al. 2014). Interestingly, 
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Pietrobono et al. (2016) demonstrated that the renewal and survival capacity of 
melanoma cells can be inhibited by indirectly targeting SOX2 using gentian violet. 
Although SOX2 seems to play an important role in therapy resistance, targeting SOX2 
directly is not a good idea due to its very important roles in different cellular processes. 
Hence, targeting SOX2 could lead to a lot of unwanted side-effects. This points out the 
importance in finding possible targets up- or downstream of SOX2 to overcome therapy 
resistance. 
1.3 CD24 
CD24 which is also called HSA (heat stable antigen) in mouse is a highly glycosylated 
cell surface molecule with a molecular mass of 30-70 kDa. This range in size is due to 
different glycosylation patterns which are highly variable and cell type dependent. As 
demonstrated in Figure 6A it is attached to the membrane by a glycosyl-
phosphatidylinositol-(GPI) anchor (Kay et al. 1991). Furthermore, the human CD24 gene 
is located on chromosome 6q21 while three intronless pseudogenes were found on 
chromosome 1, 15 and Y (Hough et al. 1994). The CD24 gene encodes for a protein of 
80 amino acids. The first 26 amino acids serve as a signal peptide to process the GPI-
anchor in the endoplasmic reticulum (ER) and are removed upon maturation of the 
protein. Without the GPI-anchor the mature human CD24 comprises only 31 amino 
acids and due to its O- and N-glycosylation sites it has mucin-like characteristics (Kay et 
al. 1991; Aigner et al. 1997; Kristiansen et al. 2004) (Figure 6). Due to its GPI-anchor, 
CD24 is preferentially located in lipid rafts which have been also termed detergent-
resistant membrane domains (DRMs) as they are highly stabile against extraction with 
surfactants. Moreover, lipid rafts are considered to be important platforms for different 
signaling molecules for example Src family tyrosine kinases and G-proteins. Actually, it 
was already demonstrated in several studies that CD24 can physically interact with 
members of the Src-kinase family and can signal via them (Zarn et al. 1996; Baumann et 
al. 2012; Sammar et al. 1997; Bretz et al. 2012). Hence, CD24 serves as a signaling 
transducer in many different cellular processes and thus also its role in cancer is highly 
investigated. Additionally, CD24 glycans are able to interact with siglecs which are a 
class of sialic acid binding receptors on immune cells (Kristiansen et al. 2010; Chen et 
al. 2009). Therefore, CD24 is important in immune response as well as in syndromes 
1 Introduction 
 
12 
 
linked to immune response like autoimmune diseases (Fang et al. 2010). Furthermore, it 
was shown that due to its P-selectin binding site (Figure 6A) CD24 serves as a ligand for 
P-selectin which supports the adhesion of monocytes and neutrophils to activated 
endothelial cells and platelets (Aigner et al. 1997 and Aigner et al., 1995)  
Figure 6: Schematic drawing and protein sequence of CD24. A: Display of a model of CD24, which is 
anchored by a GPI-anchor to the membrane. Furthermore, the core protein can be linked to N- and O-
glycans and has a P-selectin binding site. B: Amino acid sequence of the signal peptide, the mature 
peptide and the GPI-tail of mouse HSA and human CD24. In the human CD24 there is a higher amount of 
serine and threonine residues in comparison to the murine protein. Additionally the putative N-linked and 
O-linked glycans are indicated. This figure was modified from Kristiansen et al. 2004.  
1.3.1 CD24 in cancer 
CD24 overexpression was reported for a lot of different tumor types (Fang et al. 2010). 
Additionally, also the functional role of CD24 in cancer has been studied and reveals an 
important function (Figure 7). For instance, it has been shown that due to its interaction 
with P-selectin CD24 can facilitate the adhesion of breast cancer cells to the 
endothelium and thereby promote metastatic tumor progression (Aigner et al. 1998). 
Since the tumor cells can bind via CD24 to P-selectin on the platelets, they can form 
tumor thrombi. Thus, the CD24-positive tumor can dissimilate faster (Kristiansen et al. 
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2004; Agrawal et al. 2007). Moreover, a study on bladder cancer showed that CD24 can 
serve as a therapeutic target as its expression is a requirement for the development of 
lung metastases (Overdevest et al. 2011). Furthermore, it was demonstrated that CD24 
contributes to tumor cell proliferation while a depletion in CD24 leads to a stable growth 
inhibition (Sagiv et al. 2008). In addition, CD24 promotes FAK, Src and STAT3 signaling 
in cancer cells which are known to affect proliferation, adhesion and survival (Bretz et al. 
2012; Baumann et al. 2012). Moreover, CD24 was shown to increase cell proliferation 
by activating the MAPK pathway in colorectal cancer (Wang et al. 2010). Another study 
also showed that doxycyclin-induced CD24 overexpression in breast cancer cells leads 
to an increase in proliferation. By activation of integrins it also leads to an adhesion to 
fibronectin, collagen I and IV and laminin (Baumann et al. 2005). Furthermore, also a 
more rapid cell spreading, induced motility and invasion upon increased CD24 
expression was shown whereby the augmented proliferation and motility are integrin 
dependent (Baumann et al. 2005). Several other studies revealed the promoting role of 
CD24 in tumor cell adhesion, proliferation, cell motility, transmigration and invasion in 
different other tumor entities (Runz et al. 2008; Kitaura et al. 2011; Senner 1999; Mierke 
et al. 2011; Kim et al. 2007).  Smith et al. (2006) pointed out the role of CD24 in cancer 
cell survival. Moreover, as described in 1.3, CD24 interacts with siglecs and could 
thereby inhibit the immune system. Cancer cells use this system to evade the immune 
system (Fang et al. 2010). Additionally, CD24 is a marker of CSC, in some tumor entities 
while in others CD24-low cells are supposed to be the CSCs (Yang et al. 2014; Keysar 
& Jimeno 2010; Ke et al. 2012; Jaggupilli & Elkord 2012). Overall, CD24 expression 
correlates with poor prognosis in cancer patients (Fang et al. 2010).  
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Figure 7: CD24 in cancer biology. Several studies show the involvement of CD24 in different processes 
related to cancer pathogenesis.  
1.3.2 CD24 in therapy resistance 
Several studies focused on the role of CD24 in therapy resistance. A study on breast 
cancer showed the effect of CD24 knockdown and overexpression on docetaxel and 
doxorubicin resistance. They could show that a CD24 knockdown leads to a higher 
sensitivity to docetaxel while the cells are more resistant to doxorubicin. CD24-
overexpressing cells are more resistant to docetaxel but more sensitive to doxorubicin 
(Deng et al. 2017). Furthermore, another study on breast cancer showed that tamoxifen 
resistance is linked to CD24 (Surowiak et al. 2006). In agreement with this, the study of 
Goldman et al. (2015) on breast cancer matched CD24 expression to chemotherapy 
tolerance and revealed the CD24-triggered activation of the Src kinase as the reason for 
the resistance. Moreover, a study on gastric cancer showed that downregulation of 
CD24 enhances chemosensitivity (Jiao et al. 2013). Additionally, a study on endometrial 
cancer demonstrated that CD24 leads to drug resistance by the increased recruitment of 
phospho-Met to lipid rafts (Ono et al. 2015). On the opposite site, there are also several 
studies showing that a low amount of CD24 favors resistance. The study of Wang and 
collegues (2012) revealed that cells with high CD44 but low CD24 are more resistant. 
Moreover, it was shown that repressed expression of CD24 promotes resistance to 
radiation by controlling the proliferation rate as well as reactive oxygen species levels 
(Bensimon et al. 2016). Additionally, the study of Cufí et al. (2012) showed that the 
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CD24low population in breast cancer is more resistant. Therefore, the role of CD24 in 
therapy resistance seems to be drug and cell type-specific.  
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2 Aim of the study 
The most severe problem in metastatic melanoma treatment is the occurrence of 
resistance. The initially very effective treatment with inhibitors fails due to resistance 
towards these compounds. Therefore, getting a better insight into the underlying 
mechanisms of resistance could improve the therapeutic options and the chances for a 
cure for patients with metastatic melanoma. While huge effort has been made to 
understand acquired resistance, still very little is known about the mechanism of 
adaptive resistance in melanoma. Hence, studying these mechanisms of adaptive 
resistance is the primary aim of this thesis. Moreover, it has been shown in several 
studies that dedifferentiation goes along with therapy resistance. Thus, investigating the 
genes upregulated in undifferentiated and more therapy resistant induced pluripotent 
cancer cells (iPCCs) and uncovering how these genes are upregulated during inhibitor 
treatment might help to understand the underlying mechanisms.    
Taken together, there are four specific questions that should be answered in this study: 
1. Which genes are upregulated in iPCCs derived from melanoma cells as well as 
after a short-time BRAF inhibitor treatment? 
2. Does up- or downregulation of these genes change the sensitivity towards BRAF 
inhibitors? 
3. Are these genes connected and how do they lead to a survival benefit in the 
presence of the inhibitor? 
4. Finally, how are these genes upregulated in the presence of the inhibitor? 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Reagents and Kits 
Product Company Catalog No. 
Agarose NEEO Ultra 
Qualität  
Carl Roth 2267.4 
Alamar Blue® Invitrogen DAL1100  
Ammonium persulfate 
solution (APS) 
Carl Roth 9592 
Ampicillin Carl Roth HP62.1 
ARCTURUS PicoPure 
RNA Isolation Kit  
Life Technologies KIT0204  
Complete Mini Protease 
Inhibitor Cocktail 
Roche Diagnostics 04693159001  
 
Dual-Glo® Luciferase 
Assay System 
Progema E2920 
Endofree Plasmid Maxi 
Kit 
Qiagen 12362  
FITC Annexin V 
Apoptosis Detection Kit 
BD Biosciences 556547 
Fluorescence Mounting 
Medium  
Dako S3023 
High Performance 
Chemiluminescence Film 
GE healthcare 28906836  
 
HumanHT-12 v4 
Expression BeadChip Kit 
Illumina BD-103-0204 
Immobilon PVDF 
membrane, 0.45μM 
Merck Millipore IPVH00010  
 
Luminata Forte Western 
HRP Substrate 
Merck Millipore WBLUF0500 
Pierce BCA Protein Assay 
Kit 
Thermo Fisher Scientific 23225  
Proteome Profiler Human 
Phospho-RTK Array Kit 
R&D systems ARY001B 
Proteome Profiler Human 
Cytokine Array Kit 
R&D systems ARY005B 
PhosSTOPTM 
Phosphatase inhibitor 
Cocktail 
Roche Diagnostics 04906845001  
 
PageRuler Plus 
Prestained Protein Ladder 
Life Technologies 26619 
Qiaprep Spin Miniprep Kit Qiagen 27106 
Rnase-Free Dnase Set Qiagen 79254  
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RNeasy Plus Mini Kit Qiagen 74136  
 
RevertAid First strand 
cDNA Synthesis Kit 
Thermo Fisher Scientific K1622  
 
Skim milk powder Gerbu Biotechnik 1602,1000 
SYBR Green PCR Master 
Mix 
Applied Biosystems 4309155  
TEMED Carl Roth 2367.3  
Human TNF alpha ELISA 
Kit 
Abcam ab181421 
Tween® 20 Applichem A13890500  
TritonX-100 Carl Roth 3051.4  
 
X-treme GENE® 9 DNA 
Transfection Reagent 
Roche Diagnostics 06365787001 
3.1.2 Reagents for cell culture 
Product Company Catalog No. 
2-Mercaptoethanol  Gibco®Life Technologies 31350010  
Blasticidin Sigma Aldrich 15205 
DMSO  Carl Roth A994.2  
DMEM AQ mediaTM  Gibco®Life Technologies 41965-039  
Fetal Calf Serum (FCS) Biochrom S0115  
Human melanocyte 
growth supplement 
(HMGS) 100x  
Gibco® Life Technologies S002-5  
Lipofectamine® RNAiMAX 
Transfection Reagent 
Life Technologies 13778075 
Lipofectamine 2000 Life Technologies 11668030 
Medium 254 Gibco® Life Technologies M254500  
Non-essential amino 
acids 
Sigma-Aldrich M7145  
Opti-MEM® Gibco® Life Technologies 31985062 
PBS Sigma-Aldrich D8537  
Penicillin/Streptomycin Sigma-Aldrich P4333  
Puromycin Carl Roth 240.1  
Trypan blue solution Sigma-Aldrich 93595  
Trypsin  Sigma-Aldrich  T3924 
TNFα PeproTech 300-01A 
3.1.3. Human cell lines 
Cell Line  Source Cell type Mutation 
A375 ATCC Melanoma cell line BRAF V600E  
HT144 ATCC Melanoma cell line BRAF V600E  
SK Mel 28 ATCC Melanoma cell line BRAF V600E  
HEK293T ATCC embryonic kidney WT 
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cells 
3.1.4. Antibodies 
Specificity Source Company Catalog No. 
SOX2 Rabbit Cell signaling 23064S 
SOX2 Rabbit Abcam ab97959 
Src Rabbit Cell signaling 36D10 
pScr (Tyr416) Rabbit Cell signaling D49G4 
Stat3 Mouse Cell signaling 9139S 
pStat3 Mouse Cell signaling 4113S 
α-actinin Mouse Santa Cruz sc-17829 
AKT Mouse Cell signaling 2920S 
pAKT (Thr 308) Rabbit Cell signaling 4056S 
p21 Rabbit Cell signaling 2947S 
p27 Rabbit Cell signaling 2552S 
CD24 Mouse NON commercial clone SWA11 
CD24 Mouse Thermo Fisher 
scientific 
MA5-11833 
SOX10 Mouse Abcam ab181466 
MITF Mouse Abcam ab80651 
Axl Rabbit Cell signaling 4566 
ERK Rabbit Cell signaling 4695 
pERK (T202/Y204) Mouse Cell signaling 9106S 
GAPDH Rabbit Cell signaling CST2118 
NF-kappa p65 Rabbit Cell signaling 3034 
phospho NF-kappa 
p65 (Ser536) 
Rabbit Cell signaling 3033 
3.1.5 Small molecule inhibitors 
Product Company Catalog No. 
Trametinib (GSK1120212) Selleckchem S2673  
Vemurafenib (PLX4032)  Selleckchem S1267 
Dabrafenib (GSK2118436) Selleckchem  S2807 
BP-1-102 Sigma-Aldrich 573132-M 
PP2 Selleckchem S7008 
Dasatnib BioVision 1586-25 
TAPI-2 (CAS 187034-31-7) Biomol Cay14695-500 
3.1.6 siRNAs 
Product Sequence Company 
si-GFP 5’-GGC CAG GUC CAG CAG CGC ACC 
UU-3’ 
Eurofins 
si-CD24 5’-ACA ACA ACU GGA ACU UCA AUU-3’ Eurofins 
siSOX2 5’GCGUGAACCAGCGCAUGGACAGUUA-
3’ 
Invitrogen 
si-STAT3 5´-UGA AAG UGG UAG AGA AUC UUU-3´ Eurofins 
si-Src 5´-UCA AGC AGA CAU AGA AGA GUU-3´ Eurofins 
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3.1.7 Plasmids 
Name Source 
renilla plasmid pAAV psi2 Holger Sültmann (NCT, Heidelberg, Germany) 
pCMV-dR8.91 (Packaging) Konrad Hochedlinger (Harvard, Bosten, USA) 
pCMV-VSV-G (Packaging) Addgene #8454 
pGL4.10 Holger Sültmann (NCT, Heidelberg, Germany) 
pCD24-1896 Dan Theodoresu (UC Denver, Colorando, USA) 
pGL4.51 Dan Theodoresu (UC Denver, Colorando, USA) 
SOX2 OE Addgene #16577 
SOX2 KD1 TRCN0000231642 (Sigma-Aldrich) 
SOX2 KD2 TRCN0000257314 (Sigma-Aldrich) 
SOX2 KD3 TRCN0000355694 (Sigma-Aldrich) 
SOX2 KD4 TRCN0000231642; TRCN0000257314 
TRCN0000355694 (Sigma-Aldrich) 
CD24 OE HsCD00418330 (Harvard PlasmID Database) 
3.1.8 Primer 
Amplificatio
n target 
Forward Sequence Reverse Sequence 
SOX2 GCCGAGTGGAAACTTTTGTCG GGCAGCGTGTACTTATCCTTCT 
CD24 TGCTCCTACCCACGCAGATT GGCCAACCCAGAGTTGGAA 
18S  GAGGATGAGGTGGAACGTGT TCTTCAGTCGCTCCAGGTCT 
SOX10 GGCTTTCTGTCTGGCTCACT TAGAGGGTCATTCCTGGGGG 
MITF GCTCACAGCGTGTATTTTTCC TCTCTTTGGCCAGTGCTCTT 
EGFR TCCTCTGGAGGCTGAGAAAA GGGCTCTGGAGGAAAAGAAA 
Src TACTGCTCAATGCAGAGAACCC
GA 
TGTCCAGCTTGCGGATCTTGTA
GT 
STAT3 ATGGAAGAATCCAACAACGGCA
GC 
AGGTCAATCTTGAGGCCTTGGT
GA 
p75 CGACAACCTCATCCCTGTCT GCTGTTCCACCTCTTGAAGG 
Axl  CCGTGGACCTACTCTGGCT CCTTGGCGTTATGGGCTTC 
3.1.9 Solutions and Buffers  
Transfer buffer (pH 8.3)  
25mM Glycine  
190mM Tris 
20% SDS  
20% Methanol  
dH2O  
Running buffer (pH8.3) 
25mM Glycine  
190mM Tris 
0.1% SDS  
dH2O  
 
TBS 10X (pH 7.6)  
150mM NaCl  
50mM Tris  
dH2O 
Washing buffer (TBST) 
0.02% Tween® 20 
1X TBS 
Blocking buffer (milk) 
5% Skim milk powder 
1x TBS 
Blocking buffer (BSA) 
5% BSA  
1x TBS 
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Cell lysis buffer for protein isolation 
1X PhosphoStop  
1X Complete mini protease inhibitor 
cocktail  
1% Triton-X in TBS 
LB Medium  
20g LB-Medium (Carl Roth, X964.2) 
1l H2O 
SOC Outgrowth Medium  
New England BioLabs (B9020S) 
 
3.1.9 Devices  
Product Company 
AB 7500 Real-Time PCR Machine Applied Biosytems 
Classic E.O.S. Developer AGFA Mortsel, Belgium 
Nanodrop Spectophotometer ND-1000 Peqlab Biotechnologie GmbH 
Nikon Eclipse Ti Fluorescence 
Microscope 
Nikon 
FacsCanto II BD Biosciences 
Tecan Infinite F200 PRO Tecan 
Leica DM LS light microscope Leica 
3.1.10 Software  
Software name Source 
7500 Software v2.0.5 Applied Biosystems 
ApE M. Wayne Davis (Open Source) 
Chipster  Chipster Open source 
FlowJo 7.2.2  FlowJo 
GraphPad PRISM GraphPad software 
i control 1.10  TECAN 
Image J NIH  
Mendeley Mendeley 
NIS-Element  Nikon 
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3.2 Methods  
3.2.1 Cell culture 
All cell lines except normal human melanocytes (NHM) were cultured in DMEM (Gibco, 
Life Technologies) supplemented with 10 % heat-inactivated FCS (Biochrom), 0.1mM β-
mercaptoethanol (Gibco, Life Technologies), 1% non-essential amino acids (NEAA) and 
1% penicillin/streptomycin (Sigma-Aldrich). IPCCs were generated and cultured as 
described before (Bernhardt et al. 2017). All cell lines were cultured in a humidified 
incubator at 37°C and 5 % CO2. Cell lines were sub-cultured every 3-5 days as soon as 
they reached around 80 % confluency. 
NHM were isolated from the foreskin of donors in accordance to the ethical regulations 
(Ethics committee II, University Medical Centre Mannheim, Germany) and were 
afterwards cultivated in medium 254 (Gibco, Life Technologies) supplemented with 
human melanocyte growth supplement (HMGS) (Gibco, Life Technologies). 
3.2.2 Resistant cell lines 
Resistant cells were generated by gradually increasing the concentration of the inhibitor 
in the culture medium. A375 res cells (5 µM vem-resistant cells) were kindly provided by 
Prof. Dr. David Proia (Synta Pharmaceuticals Corp., Lexington, Massachusetts) and SK 
Mel 28 res cells were a kind gift from Prof. Dr. Joon Kim (Graduate School of Medical 
Science and Engineering, KAIST, Daejeon, Korea). 
3.2.3 Cell viability assay 
Melanoma cells were seeded in flat bottom 96-well plates (Gibco Life Technologies) at a 
density of 2500-5000 cells/well depending on the cell line and growth properties. The 
following day, the cells were treated with different concentrations of vemurafenib 
(plx4032), plx8394 or plx7904 (all Selleckchem), respectively, in the indicated doses. To 
compare the sensitivity to vemurafenib with the sensitivity to a combination of 
vemurafenib and PP2 (Src kinase inhibitor dissolved in DMSO), 50 µM of PP2 or the 
same volume of DMSO were added to the different concentrations of vemurafenib. After 
72h of treatment, Alamar blue (10 % of the culture medium volume) was added and after 
3,5h of incubation at 37°C the fluorescence was measured at an emission wavelength of 
3 Materials and Methods 
 
23 
 
535 nm and an excitation wavelength of 590 nm, using a Tecan Infinite F200 PRO 
(Tecan, Männedorf, Switzerland). 
3.2.4 Inhibitor treatment  
2x105 cells (for SK Mel 28 5x104 were used) were seeded in flat bottom 6-well plates 
(Gibco Life Technologies) and after attaching (within hours) they were treated with the 
inhibitor as indicated or the respective volume of solvent for control. The cells were 
incubated for 6h, 24h, 48h, 72h and 96h and afterwards RNA was isolated for qPCR or 
proteins for western blot analysis.  
In case of the Src inhibitor PP2 (Selleckchem, Munich, Germany) the cells were seeded 
one day before the 72h treatment with 50 µM PP2 or DMSO as control.  
For the STAT3 inhibitor BP-1-102 (Merck Millipore) 1x106 cells were seeded in a 10 cm 
dish one day prior to treatment. After 24h of treatment with either DMSO, vemurafenib [3 
µM], BP-1-102 [15 µM] or vemurafenib [3µM] + BP-1-102 [15 µM] or PP2 [50 µM] or PP2 
[50 µM] + vemurafenib [3 µM] the cells were harvested and lysed.  
For TAPI-2 (Biomol) treatment cells were seeded at a density of 2x105 cells/well in a 6-
well plate. The next day, the cells were treated with 10 µM TAPI-2. After 24h the cells 
were treated again with 10 µM TAPI-2. After a total of 48h the cells were harvested. 
3.2.5 TNFα stimulation 
Cells were seeded at a density of 2x105 cells/well in a 6 well plate one day prior 
treatment. At the next day the cells were treated with 10 nM TNFα. After 48h of 
treatment the cells were harvested.  
3.2.6 Puls experiment 
1x106 cells were seeded in a 10 cm dish. The next day, the cells were treated for 6h with 
vemurafenib [3 µM] or DMSO as control. Next, the cells were washed twice with pre-
warmed (37°C) medium before fresh medium was added. After overnight incubation with 
fresh medium the supernatant was transferred to naive cells seeded the day before at a 
density of 2x105 cells/well in a 6-well plate. These cells were treated with the overnight 
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supernatant for 2h, 4h, 6h and 8h and were then harvested to perform a western blot 
analysis. 
3.2.7 Transduction with lentiviral particles 
HEK293T cells were used for lentiviral particle production. The cells were grown to 
approximately 60 % confluency before transfection. For transfection, 11 μg of the 
plasmid containing the gene/shRNA of interest were mixed with the packaging plasmids 
pCMV-VSV-G (5.5 μg) and pCMV-dR8.91 (8.25 μg) and X-treme GENE® (Roche) 
solution in DMEM. After 30 min of incubation at room temperature, the mixture of DNA, 
X-treme GENE and DMEM was added to the HEK293T producer cells. After 12h, the 
supernatant was discarded. After another 12, 24, and 36 h the supernatant containing 
the virus particles was collected and the virus particles were concentrated by 
ultracentrifugation. The concentrated virus was used to infect the melanoma cells. 24h 
after the first infection the melanoma cells were re-infected with the same virus in fresh 
medium and after 48h of transduction, the cells were washed twice with PBS and then 
cultured in their culturing medium. In order to select for transduced cells, cells were 
selected for 3 days in medium containing 0.8 µg/ml of puromycin or 15 µg/ml blasticidin.   
3.2.8 Lipofectamine transfection 
Cells were seeded to 60-80 % confluency and the siRNA transfection using 
Lipofectamine™ RNAiMAX Transfection Reagent (Thermo Fisher Scientific) was 
performed according to the manufacturer’s protocol. The cells were incubated for 72h 
before use in further experiments. Transduction efficacy was monitored by qPCR and 
western blot analysis. 
3.2.9 Luciferase assay 
CD24 promoter constructs pCD24-1896 and the respective pGL4.51 control vector were 
a kind gift from Dan Theodoresu (UC Denver, Colorando, USA). The renilla plasmid 
pAAV psi2 (Börner et al. 2013) and the empty vector control pGL4.10 were a kind gift 
from Holger Sültmann (NCT, Heidelberg, Germany). In addition to these plasmids, the 
cells were co-transfected with the SOX2 OE construct (Addgene #16577) or empty 
vector as control. One day before transfection 5x103 cells were seeded in flat bottom 96-
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well plates. The next day, the cells were transfected with 100 ng total plasmid DNA. 
Thus, 66 ng of the firefly plasmids as well as 33 ng of the SOX2 OE or EV plasmid were 
transfected. Co-transfection with 1 ng renilla luciferase plasmid served as a transfection 
efficiency control. After 48h, firefly and renilla luciferase levels were determined with the 
Dual-Glo® Luciferase Assay System (Promega) according to the manufacturer’s 
instructions. Luciferase activity was normalized to renilla activity. Activities were 
calculated as the relative response ratio (RRR) whereby the positive control pGL4.51 
was 100 %. 
3.2.10 Immunoprecipitation (IP) 
Immunoprecipitation of CD24 was performed by lysing the cells of interest with 1x NP40 
lysis buffer for 30 min on ice followed by 10 min centrifugation at 14 000 rpm. The 
antibody (SWA11, 5 µg) was added to the supernatant and incubated for 1h on a 
rotating wheel at 4 °C. Next, agarose G beads were added to the antibody lysate mix to 
and incubated for 30 min at 4 °C under rotation. After washing the beads, sample buffer 
was added and the samples were cooked for 5 min at 95 °C. A western blot was run to 
visualize the result. To ensure an equal input, a small aliquot of the lysate was saved to 
serve as loading control.      
3.2.11 TMA staining 
Tumor samples from melanoma patients were used to prepare TMA-slides as reported 
before (Wagner et al. 2015). After overnight incubation with primary antibody, the slides 
were washed in TBS-T and secondary antibody staining (Dako EnVisionTM + System-
HRP; AEC K4009) was performed according to the manufacturer’s protocol. The 
samples were counterstained with H&E and mounted (Dako S3025). To ensure that the 
analyzed regions contained tumor cells, the tumor cells were stained against S100β. 
The sections were examined in a blinded setup by two individuals.  
3.2.12 Immunofluorescence 
20 000 cells were seeded in 8-well chamber slides (Falcon) in 400 µl medium. The next 
day, the cells were treated for 24h with vemurafenib [3µM] or DMSO as control. After 
24h, the cells were washed for 5 min in PBS on a shaker. Next, the cells were fixed 
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using 4% paraformaldehyde (PFA) for 5 min on ice and 10 more minutes on room 
temperature. After 5 min washing with PBS the cells were permeabilized with methanol 
for 1 min at -20°C. Followed by 5 min wash in PBS and blocking in 1% BSA/ 0.3 % 
Triton X-100 in PBS for 30 min, the cells were incubated overnight at 4 °C in a humid 
chamber with the primary antibody diluted in 1% BSA/ 0.3 % Triton X-100 in PBS (here 
pSTAT3 (cell signaling) 1:100). The next day, the cells were washed 3 times with PBS 
and afterwards incubated with the secondary antibody coupled to a fluorophore (here 
Alexa fluor 488 goat anti mouse (Invitrogen)) diluted 1:1000 in 1% BSA/ 0.3 % Triton X-
100 in PBS for 120 min protected from light in a humid chamber under constant 
agitation. After removing the antibody dilution, DAPI diluted 1:5000 in 1% BSA/ 0.3 % 
Triton X-100 in PBS was added for 10 min to the cells to visualize the nucleus. After 3 
more washes with PBS in the dark the cells were rinsed with water. Lastly, the chamber 
was removed and the slide was mounted with fluorescence mounting medium (Dako). 
The next day the cells were analyzed with fluorescence microscopy.    
3.2.13 RNA isolation and cDNA synthesis 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen). The isolation was 
performed according to the manufacturer’s protocol. If the number of cells was too small 
to use the RNeasy Kit the PicoPure RNA Isolation Kit (Thermo Fisher Scientific) was 
used. In any case, on-column DNase digestion was performed. Before further 
experiments, the RNA was quantified by using a NanoDrop ND1000 spectrophotometer 
(PEQLAB Biotechnologie GmbH, Erlangen, Germany). cDNA was transcribed using the 
Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher scientific) following the 
manufacturer’s instructions.      
3.2.14 qPCR 
To determine the expression level of mRNA quantitative real-time PCR (qPCR) was 
used. Therefore the SYBR Green Master Mix (Applied Biosystems, Life technologies) 
was mixed with cDNA and the primer of interest and the qPCR was run on a 7500 Real-
Time PCR System (Applied Biosystems, Life Technologies). As an endogenous control 
in all experiments, 18S was used. All CT values were normalized to 18S to calculate the 
2-ΔΔCt to obtain the relative gene expression. All qPCRs were run in technical triplicates 
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and the mean of the technical triplicates of at least 3 independent experiments was used 
to calculate the mean and the SEM as well as the statistical significance.  
3.2.15 Protein isolation  
After harvesting the cells were washed once with PBS and proteins were solubilized 
using lysis buffer with Complete Mini Protease Inhibitor Cocktail (Roche) and 1% Triton-
X-100. In order to maintain the phosphorylation of proteins, 1x of PhosSTOP (Roche) 
was added to the lysis buffer. The cells were lysed for 20 minutes on ice and afterwards 
centrifuged at 14 000 rpm for 15 minutes at 4 °C. The supernatant containing the 
proteins was transferred to a fresh Eppendorf tube. For the determination of the protein 
concentration, the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) was used 
following the manufacturer’s instructions.    
3.2.16 Western blot 
30 µg of protein from each sample were loaded on a 10 % SDS gel and the proteins 
were resolved according to their size by SDS-PAGE gel electrophoresis. Afterwards the 
proteins were transferred to a PVDF membrane (Merck Millipore). After blocking in 
blocking buffer, the membrane was incubated overnight at 4 °C with predetermined 
primary antibody dilution followed by washing and detection of bound antibody using 
HRP-conjugated secondary antibody for 1 hour at room temperature. To visualize the 
HRP-bound antibody, Luminata Forte Western HRP Substrate (Merck Millipore) was 
used according to the manufacturer’s instructions.  
3.2.17 Fluorescence-activated cell sorting (FACS) 
2x105 cells were seeded in 6- well plates. The next day, the cells were treated with 3 µM 
vemurafenib or DMSO as control. After 24h the cells were washed and trypsinized and 
after centrifugation resuspended in FACS buffer (PBS + 0.5 % BSA). Afterwards, the 
cells were incubated with mAb CD24 (SWA11) for 1 h. After washing, cells were 
incubated with a PE-conjugated IgG secondary antibody (Jackson ImmunoResearch) for 
30 minutes. PI and Annexin V staining were performed using the FITC Annexin V 
Apoptosis Detection Kit (BD Biosciences) following the manufacturer’s instruction. The 
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cells were analyzed by using a FacsCanto II (BD Biosciences). The acquired data were 
analyzed with the FlowJo software.  
3.2.18 Proteome Profiler Human Phospho-RTK Array Kit 
1x106 cells were seeded in a 10 cm dish. After attachment the cells were treated for 24h 
with vemurafenib [3 µM] or DMSO as control. After 24h the cells were lysed and the 
array was performed according to the manufacturer’s instructions. 
3.2.19 Proteome Profiler Human Cytokine Array Kit 
The cells were seeded in a 10 cm dish (1x106 cells/dish) and after they attached they 
were treated with vemurafenib [3 µM] or DMSO as control for 24h. The supernatant was 
harvested and processed according to the manufacturer’s instructions. 
3.2.20 TNFalpha Elisa 
Supernatant after DMSO, vemurafenib [3µM], TAPI-2 [10 µM], vemurafenib [3 µM] and 
TAPI-2 [10 µM] and TNFα [10 nM] treatment for 48h were used to perform the Elisa after 
the manufacturer’s instructions. 
3.2.21 Microarray gene expression profiling 
Total RNA isolation was performed using the RNeasy Mini Kit (Qiagen, Hilden 
Germany). After labelling, the RNA was hybridized to whole-genome BeadChips using 
the HumanHT-12 v4 Expression BeadChip Kit from ILLUMINA (Santa Clara, CA, USA) 
according to the manufacturer’s instructions. The procedure was carried out by the core 
facility of the DKFZ. Statistical analyses of hybridization data were performed using 
Chipster. To compare two groups of interest for significant differences, a Bayes test was 
used on the bead expression values of the two groups. The mean of the measured 
expressions of beads together with the standard deviation of the beads were used to 
calculate the average expression value. Only p-values lower than 0.05 were assumed as 
significantly different. Furthermore, the fold change (FC) was calculated and only genes 
with a FC outside of 1 or -1 were considered as genes whose expression changed 
between the two groups (FC is shown as log2-expression values of the differentially 
expressed genes). Some microarray data are accessible via the GEO database (iPCC 
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and HT144 data: accession number GSE95281; A375 24h DMSO/vemurafenib data: 
accession number GSE106321) others on demand. 
3.2.22 Bacterial transformation and plasmid isolation 
DH5α competent Escherichia coli (E.coli) bacteria were used for transformation and 
plasmid isolation. Therefore, 100 µl of DH5α were thawed on ice and maximum 10 µl 
DNA were added and the mix was incubated for 40 min on ice. Afterwards, the bacteria 
got a 3 min 42°C heat shock and returned in the next step for 10 min on ice. Next, 500 µl 
of SOC Medium were added and incubated for 1 hour at 37 °C under constant agitation. 
For a retransformation 50 µl were platted out on drug selection agarose plates 
containing an antibiotic for selection. Next, the plates were incubated over night at 37 
°C. On the following day, 5-6 clones were picked and were incubated over night at 37 °C 
under constant agitation in LB-medium supplemented with the antibiotic for selection. 
The next day, the plasmid was isolated by using the Qiaprep Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions. To determine if the isolated plasmid was 
correct a restriction digestion was performed. Afterwards, the bacteria carrying the 
correct plasmid were cultivated over night at 37 °C in 200 ml of LB-medium containing 
the antibiotic for selection. Next, the Endofree Plasmid Maxi Kit (Invitrogen) was used 
following the manufacturer’s description to isolate the plasmid DNA. In the last step the 
Nanodrop ND-1000 was used to determine plasmid DNA concentration and quality.   
3.2.23 Statistical analysis 
All statistics were performed using GraphPad Prism (GraphPad Software) and statistical 
tests were performed on at least 3 independent experiments if not indicated differently. 
T-Test was used when 2 groups were compared while two-way-anova was utilized for 
more than two groups. Only the microarray data were statistically analyzed using 
Chipster.   
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4 Results 
4.1 SOX2 and CD24 are upregulated in melanoma-derived iPCCs and after 
treatment with MEK/BRAF inhibitors 
A previous study from our lab showed that induced pluripotent cancer cells (iPCCs) 
generated from melanoma cells by stable reprogramming with the transcription factors 
OCT4, KLF4, and SOX2 are more resistant towards targeted therapy (MEK and BRAF 
inhibitors) than their parental counterpart (Bernhardt et al. 2017). Using microarray 
expression data of these iPCCs and their parental counterpart, a significant increase of 
SOX2 and CD24 expression was observed in HT144-iPCCs in comparison to the 
parental HT144 cells (Figure 8A). Due to the ectopic overexpression of SOX2 during 
reprogramming a high expression level of SOX2 was expected. Notably, when 
comparing this data set with genes changed in A375 cells after 24h of vemurafenib 
(vem) treatment, SOX2 and CD24 were also significantly upregulated (Figure 8B). The 
microarray data were further confirmed by qPCR and western blot (WB) to ensure that 
the increase is also detectable with other methods than microarray expression analysis 
(Figure 8). Since SOX2 and CD24 expression was increased in BRAF inhibitor (BRAFi) 
and MEK inhibitor resistant melanoma-iPCCs as well as in melanoma cells treated for a 
short time with the inhibitor, the role of SOX2 and CD24 in adaptive resistance became 
the focus of attention of this work.  
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Figure 8: SOX2 and CD24 are highly upregulated in BRAFi-resistant melanoma iPCCs and in short-
time BRAFi-treated melanoma cells. A: Microarray data from HT144-iPCCs in comparison to the 
parental HT144 cells show a significant upregulation of SOX2 and CD24 in the iPCCs (FC= fold change in 
log2 scale). The two graphs on the right show validation of microarray data by qPCR. qPCR data are 
shown as the relative expression level of mRNA, normalized to 18S (n=2). B: Microarray data from A375 
treated for 24h with 3 µM vemurafenib or the corresponding amount of DMSO show significant 
upregulation of SOX2 and CD24 after vemurafenib treatment. This was also validated by western blot 
(WB). α-actinin served as loading control. 
To determine the time of treatment which is necessary to observe an upregulation of 
CD24 and SOX2, different BRAF-mutated melanoma cell lines (A375, HT144, SK Mel 
28) were treated for various time periods with BRAFis (vemurafenib, plx8394, plx7904). 
All melanoma cell lines showed a significant upregulation of SOX2 and CD24 on the 
mRNA level after BRAFi treatment. The time periods, however, varied from cell line to 
cell line (Figure 9A-F).   
Since MEK and BRAF inhibitors are used in combination with each other in melanoma 
therapy, A375 melanoma cells were treated simultaneously with the BRAFi vemurafenib 
and the MEK inhibitor trametinib. As demonstrated in Figure 9G, again, a significant 
increase in SOX2 and CD24 expression was determined by qPCR.  
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Figure 9: Short-time treatment with BRAFis as well as with a combination of MEK and BRAFis 
resulted in an upregulation of SOX2 and CD24 expression. A: SOX2 is significantly upregulated after 
different time periods of BRAFi (vemurafenib, plx8394, plx7904) treatment [3 µM] in A375 cells. B: CD24 
is significantly unregulated after treatment with BRAFi in A375 cells. C: HT144 cells show increased level 
of SOX2 after short-time BRAFi treatment [3 µM]. D: CD24 is upregulated in HT144 cells after short-time 
treatment with BRAFi. E: SK Mel 28 cells show an increase in SOX2 expression after short-time of BRAFi 
treatment. F: CD24 is upregulated in SK Mel 28 cells after different time periods of treatment with BRAFi. 
G: A375 cells were treated for 24h with a combination of vemurafenib (v) and trametinib (t) (each 3 µM). 
SOX2 and CD24 are higher expressed in the treated cells in comparison to DMSO control cells. All data 
are shown as relative expression level of mRNA, normalized to 18S (p < 0.05 *; p < 0.01 **; p < 0.001 ***) 
Moreover, to ensure that the increased expression is due to an upregulation of the 
protein rather than the result of selective killing flow cytometric analysis after PI and 
Annexin-V staining was performed to detect apoptotic cells. This experiment revealed 
that the vemurafenib-mediated upregulation of CD24 was due to induction of expression 
and not the result of selective cell death of CD24-negative cells (Figure 10). Together, 
these data suggest that SOX2 and CD24 might play a role in adaptive resistance. 
 
Figure 10: Elevated number of CD24-positive cells is due to increase of CD24 expression and not 
due to selection. A: Double staining with PI and AnnexinV combined with FACS analysis show that the 
apoptotic cell population is increased after 24h of vemurafenib treatment (3 µM). B: Double staining of 
CD24 and AnnexinV in FACS shows that vemurafenib treatment increases the amount of apoptotic cells 
and the amount of living CD24-positive cells.   
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4.2 Vemurafenib treatment or overexpression of SOX2 show a more neural 
crest cell like phenotype 
To investigate if the vemurafenib treated cells have a more dedifferentiated phenotype 
the microarray data of vemurafenib-treated as well as DMSO-treated cells were 
compared to microarray data of normal human melanocytes (NHM) and neural crest 
(NC) cells. Interestingly, the DMSO-treated A375 cells clustered in a heat map together 
with NHMs while A375 cells treated with vemurafenib were more close to NC cells which 
represent a more undifferentiated phenotype (Figure 11). Noteworthy, SOX2-
overexpressing (OE) A375 cells were more close to vemurafenib-treated and NC cells 
while A375 cells transduced with an empty vector (EV) control clustered together with 
DMSO-treated cells and NHMs (Figure 11). Hence, it can be concluded that melanoma 
cells treated with vemurafenib as well as cells overexpressing SOX2 have a more 
undifferentiated phenotype. 
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Figure 11: SOX2 overexpression or vemurafenib treatment favors a more undifferentiated 
phenotype. Heat map representation of microarray data shows clustering of A375 empty-vector control 
cells (EV) with DMSO–treated control cells and normal human melanocytes (NHMs) while SOX2-
overexpressing cells (OE) cluster with vemurafenib-treated [3 µM 24h] and neural crest cells (NCs).  
4.3 SOX2 regulates the expression of CD24 
To investigate if there is connection between the SOX2 and the CD24 expression or if 
they are independently upregulated, SOX2 was overexpressed in the melanoma cell 
lines A375 and SK Mel 28. Subsequently, the level of CD24 expression was examined. 
A significant increase of CD24 expression on both mRNA and protein level was 
observed (Figure 12A&B) while no increase in SOX2 expression was noticed upon 
CD24 OE (data not shown). 
To corroborate these data in clinical samples of metastatic melanoma patients, a TMA of 
60 tissues stained by IHC was analyzed for SOX2 and CD24 expression. A significant 
positive correlation (r=0.4; p=0.004) between SOX2 and CD24 expression was observed 
using pearsons correlation (Figure 12C).  
Next, it was investigated if SOX2 regulates CD24 at the transcriptional level. Therefore, 
the CD24 promotor was examined for potential SOX2 binding sites. By using the 
JASPAR prediction tool (http://jaspar.genereg.net) 6 putative binding sites for SOX2 
were identified in the CD24 promoter as displayed in Figure 12D. The luciferase assay 
was utilized to measure if SOX2 directly binds to the CD24 promotor at these sites. The 
assay was performed by using the CD24-promoter luciferase construct published 
elsewhere (Overdevest et al. 2012). This luciferase construct includes the whole 
promoter upstream of the luciferase gene. For this assay SOX2 was transiently 
overexpressed in HEK293T cells as well as in A375 cells (Figure 12E&G) whereby the 
overexpression in HEK293T cells was more effective than in A375 cells. The plasmids 
for transient overexpression were co-transfected with the CD24 promotor-luciferase 
reporter plasmid as well as with a CMV promotor driven Renilla plasmid as control. This 
resulted in an increased luciferase activity compared to the control cells that had been 
transfected with an empty control vector instead of the SOX2 OE construct (Figure 12 
F&H). 
These data are consistent with published CHIP-Seq data on the overexpression of 
SOX2 in human embryonic stem cells and human skin fibroblasts. These data reveal a 
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binding of SOX2 to the CD24 promotor at position -1342 with reference to the 
transcription start site (Tsankov et al. 2015; Soufi et al. 2012; GEO acession number: 
GSM1505768; GSM896986). Hence, the most likely binding site of SOX2 in the CD24 
promotor is the one indicated by a circle in Figure 12D.  
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Figure 12: CD24 is regulated by SOX2 and their levels are correlated in metastatic melanoma 
patient samples. A: Left: Validation of SOX2 overexpression (OE) in A375 cells by qPCR showing 
relative expression level of mRNA, normalized to 18S, EV= empty vector. Middle: qPCR Data showing 
increase of CD24 expression in SOX2 OE in comparison to EV A375 cells. Right: Confirmation of qPCR 
data by WB B: Left: SOX2 OE in SK Mel 28 cells was validated by qPCR. The SOX2 OE cells have a 
significantly higher expression level of SOX2. Middle: qPCR data showing a significant increase in CD24 
expression in SK Mel 28 SOX2 OE cells in comparison to EV control cells. Right: WB analysis of the 
CD24 level after SOX2 OE. An immunoprecipitation against CD24 in lysate of the same protein 
concentration was performed to enrich the amount of CD24. CD24 is highly increased in the SK Mel 28 
SOX2 OE cells. C: Left: IHC staining of a TMA of metastatic melanoma patient samples stained for SOX2, 
CD24 and S100β as indicated. The top row shows an example for a low score of SOX2, CD24 while the 
sample for sure contains tumor cells as demonstrated by the marker S100β. The lower row shows a TMA 
sample highly positive for SOX2 and CD24. S100β serves as a marker for tumor cells. Right: Pearson’s 
correlation analysis of CD24 and SOX2 IHC reveals positive correlation of SOX2 and CD24 expression 
levels in metastatic melanoma samples of patients. D: Schematic drawing of CD24 promotor with its 
potential SOX2 binding sites followed by the luciferase reporter as it is used in the luciferase assay. The 
most likely binding site due to ChIPseq data is highlighted with a circle. The plasmids were transiently 
transfected into HEK and A375 cells either together with a SOX2 OE plasmid or an EV control for 48 h. 
The CMV promotor served as positive control and the pGL4.10 empty vector was used as negative 
control. E: Transient OE of SOX2 in HEK cells validated by qPCR.  F: The luciferase activity dependent 
on the SOX2 expression level was measured and all were normalized to the Renilla luciferase activity. 
The Relative Response Ratio (RRR) is significantly higher in the SOX2-overexpressing HEK cells. G: 
Validation of transient SOX2 OE in A375 cells by qPCR, showing increased SOX2 expression upon 
overexpression. H: Luciferase assay reveals a slight increase of the luciferase activity upon transient 
SOX2 OE as demonstrated by the increased RRR. (p < 0.05 *; p < 0.01 **; p < 0.001 ***) 
4.4 SOX2 or CD24 overexpression augments resistance towards 
vemurafenib and induces activation of Src and STAT3  
Next, it was elucidated whether an increased expression level of SOX2 would influence 
the resistance towards vemurafenib treatment. Two different melanoma cell lines (A375 
and SK Mel 28) either transfected with a constitutively active SOX2 OE construct or an 
EV as control were treated with increasing concentrations of vemurafenib to determine 
the IC50. This experiment revealed a significant increase in the IC50 value in SOX2-
overexpressing cells compared to empty vector control cells (i.e.: A375: EV mean IC50= 
165 nM, SOX2 OE mean= 269 nM; p value= 0.045) (Figure 13A). In accordance with 
this also an overexpression of CD24 resulted in an increased resistance towards BRAFi 
treatment when compared to empty vector control cells (Figure 13B). Hence, CD24 OE 
can mimic the effect of SOX2 OE. 
To investigate which downstream pathways could be important for the increased 
resistance induced by SOX2 or CD24 OE we investigated the change in activity of Src 
and STAT3. These were shown before in other human carcinoma cells to have an 
4 Results 
 
39 
 
increased activity upon CD24 OE (Bretz et al. 2012). Thus, it might be possible that the 
SOX2-mediated upregulation of CD24 cause a similar effect in melanoma cells. Indeed, 
an increased phosphorylation of Src, STAT3 and ERK was observed upon SOX2 OE in 
A375 and SK Mel 28 melanoma cell lines that could be related to the increased 
resistance towards vemurafenib (Figure 13C). CD24 OE in A375 cells led to comparable 
results (Figure 13D). Therefore, Src and STAT3 activity might play an important role in 
the SOX2 and CD24-mediated resistance. 
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Figure 13 Upregulation of SOX2 or CD24 goes along with increased resistance towards BRAFi and 
activation of Src, STAT3 and ERK. A: SOX2-overexpressing (OE) A375 and SK Mel 28 cells showed a 
higher IC50 than empty vector (EV) control cells and were therefore less sensitive towards vemurafenib. 
B: CD24 OE A375 cells showed a higher IC50 when compared to EV control cells. Therefore these cells 
could tolerate a higher concentration of vemurafenib, plx8394, plx7904. C: WB showing an increased 
activation of Src, STAT3, and ERK in SOX2-overexpressing A375 and SK Mel 28 cells D: CD24 OE in 
A375 cells resulted in an increased activation of Src, STAT3 and ERK.  
4.5 Src or STAT3 inhibition is still effective in SOX2 OE and CD24 OE cells 
To investigate if the more resistant SOX2 and CD24 OE cells can still be targeted by 
using Src or STAT3 inhibitors viability assays were performed where the cells were 
treated with Src or STAT3 inhibitors in addition to vemurafenib. 
4 Results 
 
41 
 
Figure 14A shows that PP2 is an effective inhibitor of Src but has no effect on STAT3 
activity. When SOX2 OE or CD24 OE A375 cells were treated with PP2 in addition to 
vemurafenib the cells showed a significantly lower IC50 compared to treatment with 
vemurafenib and DMSO control (Figure 14B&C). 
Interestingly, vemurafenib-induced phosphorylation of STAT3 was blocked in the 
presence of the STAT3-specific inhibitor BP-1-102 but was not affected in the presence 
of the Src inhibitor PP2 (Figure 14D). Similar results were obtained with another Src 
inhibitor, dasatinib (data not shown). When SOX2 or CD24 OE cells were treated with 
BP-1-102 in addition to vemurafenib a decreased IC50 was determined (Figure 14E&F). 
Hence, these data are comparable with data obtained in the vemurafenib and PP2 
treatment experiment (Figure 14B&C).  
Thus, the results obtained here suggest that the activation of STAT3 is not dependent 
on Src phosphorylation and that SOX2 and CD24 might induce adaptive resistance via 
Src and STAT3 activation. For this reason, targeting Src or STAT3 might be beneficial to 
overcome adaptive resistance. 
Figure 14: Inhibition of Src or STAT3 is still effective in the more resistant SOX2 or CD24-
overexpressing cells. A: SOX2-overexpressing (OE) A375 cells were treated with PP2 [50 µM], an 
inhibitor of Src. WB showing Src inactivation but no changes in STAT3 activation. B, C: Treatment of 
SOX2 OE or CD24 OE A375 cells with PP2 [50 µM] in addition to vemurafenib leads to a decreased IC50. 
D: STAT3 is activated by vemurafenib [3 µM] and can be inhibited by BP-1-102 [15 µM] but not by PP2 
[50 µM]. E, F: the more resistant SOX2 OE/ CD24 OE A375 cells can still be killed by the STAT3 inhibitor 
BP-1-102 as demonstrated by the lower IC50 value of the cells treated with BP-1-102 in addition to 
vemurafenib. (p < 0.05 *; p < 0.01 **; p < 0.001 ***) 
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4.6 SOX2 or CD24 knockdown result in a higher sensitivity towards BRAFis 
To further analyze the impact of SOX2 on cell viability and BRAFi resistance, a stable 
knockdown (KD) of SOX2 via shRNA was used. Several clones (KD1-4) showing SOX2 
depletion were established (Figure 15A-C). SOX2 KD in A375 (Figure 15A), HT144 
(Figure 15B) or SK Mel 28 (Figure 15C) which all represent BRAF mutant cell lines, led 
to a higher sensitivity towards BRAFis indicated by the lower IC50 values than the 
respective scramble control cells. Additionally, the effect of CD24 KD on cell viability was 
examined. To check if knockdown of CD24, which is a downstream effector of SOX2, 
can hamper the cells resistance, the more resistant SOX2 OE cells were transiently 
transfected with siRNA targeting CD24. As demonstrated in Figure 15D the KD of CD24 
in SOX2-overexpressing cells resulted in an increased sensitivity towards BRAFis. To 
confirm earlier results for melanoma, the effect of CD24 KD on activation of Src and 
STAT3 was studied (Bretz et al. 2012). As expected the KD of CD24 resulted in a 
decreased activity of Src and STAT3 (Figure 15E) in melanoma cells and therefore 
confirmed the results obtained from other carcinoma cells. Interestingly, CD24 seems to 
play an important role in melanoma patient survival (Figure 15F). The data revealed that 
CD24 expression negatively influences patient survival since a higher expression of 
CD24 can be found in short-time survivors in comparison to long-time survivors. Taken 
together, these results suggest that in melanoma cells SOX2 and CD24 play an 
important role in conferring BRAFi resistance and possibly other tumor feature via 
regulating Src and STAT3 activity. 
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Figure 15: KD of SOX2 or CD24 causes a higher sensitivity towards BRAFi treatment. A: WB 
demonstrating that the shRNA-mediated knockdown (KD) of SOX2 in A375 cells is effective. A375 cells 
with a KD of SOX2 show a higher sensitivity towards vemurafenib. B: WB to validate shRNA-mediated KD 
of SOX2 in HT144 cells and the effect of SOX2 KD on the viability of HT144 cells. C: KD of SOX2 makes 
the SK Mel 28 cells more sensitive towards BRAFi treatment. D: siRNA KD of CD24 in SOX2-
overexpressing A375 cells results in a decreased resistance towards BRAFi treatment as shown by the 
lower IC50 in the CD24 KD cells. E: siRNA-mediated KD of CD24 leads to a decreased activation of Src 
and STAT3 in SOX2 OE A375 cells. F: TMA staining of melanoma patient specimens were analyzed for 
the CD24 expression and classified into short-time survivors (<12 months; n=57) and long-time survivors 
(>12 months, n=41). The results revealed a significantly higher CD24 expression in short-time survivors in 
comparison to long-time survivors. (p < 0.05 *; p < 0.01 **; p < 0.001 ***) 
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4.7 STAT3 activation is required for SOX2 and CD24 induction 
To examine the upstream regulators of SOX2 and CD24 during vemurafenib treatment, 
the SOX2 and CD24 expression in dependence of STAT3 activity was investigated. 
STAT3 is a transcription factor that after being phosphorylated at tyrosine 705 dimerizes 
and translocates to the nucleus, where it binds to target genes and promotes 
transcription (Darnell 1997). Figure 16 shows that upon vemurafenib treatment 
phosphorylated STAT3 was increased and translocated to the nucleus where it can 
regulate its target genes. It could be shown that the increase of SOX2 and CD24 
expression upon vemurafenib treatment was linked to STAT3 activation (Figure 17A-C). 
Figure 17 illustrates that inhibiting STAT3 by the STAT3-specific inhibitor BP-1-102 
during vemurafenib treatment diminished the vemurafenib-induced increase of SOX2 
and CD24 expression on protein and mRNA level. Furthermore, an early activation of 
STAT3 was noticed. It was detectable already 6 h after onset of treatment (Figure 17D). 
Moreover, SOX2 and CD24 were upregulated upon vemurafenib treatment when STAT3 
was activated. Src on the other hand showed only a slight increase in activity after 24h 
of vemurafenib treatment (Figure 17D). Additionally, siRNA KD of STAT3 or Src was 
used to investigate their influence on SOX2 and CD24 expression. Indeed, siRNA-
mediated STAT3 KD resulted in a decrease of SOX2 and CD24 expression while Src 
KD showed no effect (Figure 17E). These data clearly suggest that STAT3 activation is 
required for the induction of SOX2 and CD24 expression in A375 melanoma cells upon 
vemurafenib treatment. A similar regulation of SOX2 by STAT3 in neural precursor cells 
(Foshay & Gallicano 2008) and the binding of STAT3 to the SOX2 promoter in 
melanoma cells were shown before (Pietrobono et al. 2016). 
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Figure 16: Phosphorylated STAT3 is increased and transferred to the nucleus upon vemurafenib 
treatment. DAPI (blue) stains the nucleus of all cells. pSTAT3 was stained with an antibody which 
specifically detects STAT3 phosphorylated at tyrosine 705 (green). A375 cells treated with vemurafenib 
[3µM; 24h] showed an increase in pSTAT3 mainly located in the nucleus.  
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Figure 17: STAT3 activation by vemurafenib is essential for increased SOX2 and CD24 expression. 
A: WB of A375 cells treated for 24h with DMSO, vemurafenib [3 µM], BP-1-102 [15 µM], vemurafenib [3 
µM] + BP-1-102 [15 µM]. The WB shows that the increased STAT3 activation upon vemurafenib treatment 
could be inhibited in the presence of the STAT3 inhibitor BP-1-102. Furthermore the vemurafenib induced 
SOX2 and CD24 expression was reduced when the STAT3 inhibitor was present in addition to 
vemurafenib B, C: qPCR data confirming the WB results for SOX2 (B) and CD24 (C) on the mRNA level. 
qPCR showing relative expression level of mRNA, which is normalized to 18S. D: WB of A375 cells 
treated for the indicated times with 3 µM vemurafenib or DMSO as control. The STAT3 activation is 
depicted by pSTAT3 and was increased after 6h of vemurafenib treatment. Furthermore, SOX2 was also 
increased after 6h vemurafenib treatment while a high increase in CD24 was detected after 24h of 
vemurafenib treatment. Src was slightly activated after 24h vemurafenib treatment as depicted by the 
increase in pSrc. E: A375 cells were treated with siRNA against GFP as control, STAT3 and Src. SOX2 
and CD24 were downregulated by siRNA knockdown (KD) of STAT3 but were unchanged after Src KD. (p 
< 0.05 *; p < 0.01 **; p < 0.001 ***) 
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4.8 Vemurafenib-induced NF-kappa B activation is an early event and 
sheddases play an important role in STAT3 activation  
To study how vemurafenib can activate STAT3 the activation of NF-kappa B was 
examined as it was previously shown that NF-kappa B is able to activate STAT3 
promoting a more dedifferentiated phenotype (Agarwal & Zambidis 2014). The results 
revealed an NF-kappa B activation already after 30 min of vemurafenib treatment while 
STAT3 was activated 6h after treatment (Figure 18A). As NF-kappa B activation can 
cause the release of soluble factors (Kulms & Schwarz 2006) which then might activate 
STAT3 it was studied if the supernatant alone was able to activate STAT3. Therefore, 
cells were pulsed for 6h with vemurafenib or DMSO as control. Next, the cells were 
washed and fresh medium was added over night. At the next day, the supernatant was 
transferred to naive cells and the cells were incubated with this medium for the indicated 
time. The results revealed that the supernatant of the vemurafenib pulsed cells alone 
was able to activate STAT3 (Figure 18B). Thus, soluble factors were the reason for the 
vemurafenib-induced STAT3 activation. To investigate which are the factors responsible 
for the STAT3 activation a cytokine array was performed. The cytokine array showed 
that cytokines present on the human cytokine profiler such as IL-6 or CCL2 were not the 
reason for the increased STAT3 activation in these settings (data not shown). Hence, it 
still needs to be investigated which soluble factors activate STAT3. Interestingly, the 
vemurafenib-induced STAT3 activation as well as the increased expression of SOX2 
and CD24 could be diminished by using TAPI-2, which is an inhibitor of ADAMs (a 
disintegrin and metalloproteinase) (Figure 18C). ADAMs shed transmembrane domains 
of extracellular proteins (i.e. different receptor ligands and cytokines) and are therefore 
classified as sheddases. Recently, it was published that vemurafenib induces TNFα 
(tumor necrosis factor alpha) which then activates NF-kappa B (Lehraiki et al. 2015). For 
this reason, it was investigated if TNFα was present in the supplement and responsible 
for the increased STAT3 activation and the induction of expression of SOX2 and CD24. 
The administration of recombinant TNFα did not activate STAT3 or increase the 
expression of SOX2 and CD24 (Figure 18C). Moreover, a TNFα Elisa showed no 
increase in TNFα in the supernatant after vemurafenib treatment (data not shown). 
Hence, TNFα was not the player mediating the vemurafenib-induced STAT3 activation 
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and therefore not responsible for the increase in SOX2 and CD24 expression upon 
vemurafenib treatment. In summary, these data suggest that the vemurafenib-induced 
activation of STAT3 was triggered most likely by soluble factors cleaved by ADAMs. 
  
 
Figure 18: NF-kappa B (p65) activation is an early event after vemurafenib treatment followed by 
STAT3 activation. STAT3 is activated by a soluble factor cleaved by a sheddase. A: NF-kappa B 
(p65) showed an increased activation upon 30 min of vemurafenib treatment while STAT3 was activated 
by vemurafenib after 6h of treatment. B: A375 cells were pulsed for 6h with vemurafenib [3 µM] or DMSO 
as control. Then the medium containing vemurafenib or DMSO was exchanged with fresh medium after 
washing the cells. The next day the supernatant was transferred to fresh cells for the times indicated in the 
WB. STAT3 could be activated with the vemurafenib-pulsed supernatant after 4h. CD24 and SOX2 also 
showed a slight increase. C: The vemurafenib-induced STAT3 activation after 48h could be inhibited by 
the addition of TAPI-2 [10 µM] which inhibits sheddases while TNFα could not activate STAT3. Moreover, 
vemurafenib increased the expression of SOX2 and CD24. This increase was reduced by adding TAPI-2 
[10 µM] to vemurafenib [3 µM]. 
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4.9 Receptor tyrosine kinase (RTK) activation can be influenced by 
vemurafenib treatment  
To investigate if RTKs are differentially activated after vemurafenib treatment an array 
screening different RTKs was performed. Figure 19 shows an increased activation of 
ErbB3 (Erb-B2 receptor tyrosine kinase 3) and M-CSF R (monocyte colony stimulating 
factor receptor) while Dtk (TYRO3 protein tyrosine kinase), EphA2, EphA4, EphA7 
(ephrin receptors) and DDR1 (discoidin domain receptor tyrosine kinase 1) are less 
phosphorylated in comparison to the DMSO control. Most interesting was the ErbB3 
activation upon vemurafenib treatment as this was already shown to play an important 
role in adaptive resistance (Kugel & Aplin 2014). Hence, ErbB3 activation might be 
responsible for the vemurafenib induced STAT3 activation and thereby cause an 
increased SOX2 and CD24 expression after vemurafenib treatment. 
 
Figure 19: Vemurafenib-treatment can change the RTK phosphorylation. Phosphorylation of receptor 
tyrosine kinases (RTK) after 24h of vemurafenib [3 µM] treatment was compared to DMSO control 
treatment by using a Phospho-RTK array (bars represent mean of technical duplicates, SEM< 5%) 
4.10 SOX2 and CD24 are not crucial in acquired therapy resistance   
To investigate if SOX2 or CD24 play also an important role in acquired resistance, 
resistant cell lines were established. Figure 20A illustrates the higher drug tolerance of 
the resistant cells in comparison to their parental cell lines to confirm their resistance. 
During the acquisition of resistance some cell lines changed their morphology as shown 
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in Figure 20B while others showed the same morphology as their parental counterparts 
(data not shown). Microarray analysis was performed to investigate the differential gene 
expression in resistant and parental cells. In terms of SOX2 or CD24 only an increased 
expression of SOX2 could be detected in resistant HT144 cells (HT144 res cells) (FC>1) 
while CD24 was only upregulated in resistant SK Mel 28 cells (SK Mel 28 res cells) 
(Figure 21A&B). The CD24 and SOX2 expression was also analyzed on mRNA level via 
qPCR showing a significantly increased SOX2 expression in HT144 res cells in 
comparison to parental cells while SK Mel 28 res cells displayed a significant 
downregulation of SOX2 (Figure 21 C). In contrast, CD24 was significantly increased in 
SK Mel 28 res cells and vemurafenib-resistant A375 res 7 µM vem cells (Figure 21D). 
The analysis on protein level confirmed the results obtained from qPCR for SOX2 while 
an upregulation of CD24 was observed in trametinib resistant A375 res 130 nM tra cells 
instead of in A375 res 7 µM vem cells (Figure 21E). Thus, no correlation between SOX2 
and CD24 expression in cells with acquired resistance was observed.  
Furthermore, it was investigated if siRNA KD of SOX2 in cells with acquired resistance 
could restore sensitivity towards the inhibitor since in naive cells a KD of SOX2 resulted 
in an increased sensitivity. Figure 21F&G show that siRNA-mediated SOX2 KD did not 
change the sensitivity towards the BRAFi. Interestingly, it was observed that when the 
resistant cells were treated with a higher concentration of the BRAFi no significant 
increase in SOX2 or CD24 expression could be detected (Figure 21H&I). Taken 
together, these results reveal a role of SOX2 and CD24 in adaptive resistance but not in 
acquired resistance. 
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Figure 20: Resistant cells can tolerate a higher dose of the inhibitor they are resistant to and some 
change their morphology. A: Resistant (res) and parental cells were treated with increasing 
concentrations of the inhibitor they were resistant to. The res cells could tolerate a higher dose of the 
inhibitor as indicated by the higher IC50 value confirming their resistance. B: Some of the resistant cells 
changed their morphology. (p < 0.05 *; p < 0.01 **; p < 0.001 ***) 
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Figure 21: SOX2 and CD24 do not play a role in acquired resistance. A: Microarray analyses revealed 
that the level of SOX2 was only changed (FC: >1; <-1) in vemurafenib-resistant HT144 cells (HT144 res), 
in comparison to parental cells. B: CD24 was only changed in SK Mel 28 res cells in comparison to 
parental cells. C: qPCR data showed a significant SOX2 upregulation in vemurafenib-resistant HT144 
cells and downregulation in vemurafenib-resistant SK Mel 28 cells in comparison to parental cells. D: 
CD24 was significantly increased in A375 res  7 µM vem cells and in SK Mel 28 res cells. E: WB showing 
the expression of SOX2 and CD24 in parental and resistant cells. F/G: siRNA KD of SOX2 could not 
restore sensitivity in the resistant A375 (F) and HT144 (G) cells. H/I: Treating the resistant cells with a 
higher dose of vemurafenib (as indicated) for 24h did not lead to a significant change in the SOX2 and 
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CD24 expression in A375 (H) and SK Mel 28 (I) res cells. A375 7V= A375 res 7 µM vem cells; SK Mel 28 
2V=SK Mel 28 res 2 µM vem cells. (p < 0.05 *; p < 0.01 **; p < 0.001 ***)  
4.11 Deregulated pathways and molecules in cells with acquired resistance    
To further characterize the cells that acquired resistance, different pathways and 
molecules which might be deregulated were analyzed. First, the ERK activation in the 
resistant cells was examined showing an increased activity of ERK in all resistant cell 
lines in comparison to the parental cells. AKT activity was only increased in HT144 res 
cells and SK Mel 28 res cells. Interestingly, Src showed an increased activity in HT144 
res cells while it was decreased in A375 res 7 µM vem cells. Moreover, STAT3 activity 
was high in A375 res 5 µM vem cells as well as in A375 res 130 nM tra and SK Mel 28 
res cells (Figure 22A). 
As the modified expression of Axl, MITF and SOX10 were shown to play a role in 
resistance (Müller et al. 2014; Sun et al. 2014) the expression of these molecules was 
examined. A decreased MITF and SOX10 expression in SK Mel 28 res cells was 
observed on mRNA and protein level while the Axl expression was increased. The MITF 
expression was also slightly downregulated in all other resistant cell lines while the 
SOX10 expression was also downregulated in A375 res 7 µM vem and A375 res 130nM 
tra cells as well as in HT144 res cells (Figure 22B-E). Hence, some resistant cells 
showed a modified expression of Axl, SOX10 and MITF. 
As a change in EGRF expression was also shown to be involved in the establishment of 
resistance (Sun et al. 2014; Manzano et al. 2016), the EGFR expression in resistant 
cells in comparison to their parental counterpart was analyzed. No significant changes 
were noticed (Figure 22F).  
Interestingly, microarray data of resistant and parental cells analyzed with Ingenuity 
Pathways Analysis revealed an altered activity of the TGFβ pathway in nearly all 
resistant cell lines (except A375 res 130nM tra cells). Moreover, this analysis also 
showed a change in cell survival as well as cellular movement and proliferation in the 
resistant cells. The genes changed in the majority of the resistant cell lines (all except 
A375 res 5 µM vem cells) were among others upregulated NUPR1 (nuclear protein 1), 
which promotes tumor repopulation and cell growth, as well as downregulated anti-tumor 
genes SFRP1 (secreted frizzled-related protein 1) and RUNX3 (runt-related transcription 
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factor 3) and the inhibitor of cell growth, metastasis and invasion AGPAT9 (1-Acyl-Sn-
glycerol-3-phosphate O-acyltransferase 9).  
 
Figure 22: Characterization of resistant cells. A: WB analyses of pathways which might be deregulated 
after acquiring resistance. ERK is more activated in resistant cells in comparison to parental cells. AKT is 
more strongly activated in HT144 res cells and in SK Mel 28 res cells in comparison to parental cells while 
in A375 res 7 µM vem and A375 res 130 nM tra AKT is even inactivated. Src is activated in HT144 res 
cells and inhibited in A375 res 7 µM vem cells and SK Mel 28 res cells. STAT3 activation is increased in 
A375 res 5 µM vem, A375 res 130 nM tra and SK Mel 28 res cells. B/C/D: Determination of Axl, MITF and 
SOX10 expression by qPCR showing relative expression level of mRNA, normalized to 18S. E: Protein 
expression of Axl, MITF and SOX10 in resistant and parental cells. F: Change in EGFR RNA expression 
in resistant cells in comparison to parental cells. 
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4.12 Cell cycle analysis reveals an increased expression of the cyclin-
dependent kinase inhibitors p27 and p21  
To further investigate if the resistant cells have an altered cell cycle regulation, the 
expression of p27 and p21 was examined. Figure 23 illustrates that some of the 
resistant cell lines showed a change in the expression of the cell cycle regulators p27 
and p21. In A375 res 5 µM vem as well as in A375 res 130nM tra, HT144 res and SK 
Mel 28 res cells an increased expression of p27 in comparison to their parental cells was 
visible. Moreover, an increase in p21 was detected in SK Mel 28 res cells compared to 
the parental cell line. Both, p27 and p21, are inhibitors of cyclin-dependent kinases 
(CDKs). CDKs regulate together with cyclins the transition from G1 phase to S phase or 
if the cells are in G2 they initiate mitosis. Hence, CDKs promote proliferation. As 
inhibitors of CDKs, p27 and p21 inhibit proliferation and thus the resistant cells have a 
less proliferative phenotype. Furthermore, p27 and p21 have also been demonstrated to 
play a role in apoptosis (Coqueret 2003). 
 
Figure 23: Cell cycle analysis of parental and resistant cells. Increased expression of p21 or p27 
revealed a less proliferative phenotype because the cell cycle is arrested in G1. In A375 res 5 µM vem 
cells, A375 res 130 nM tra cells and in HT144 and SK Mel 28 res cells p27 is more strongly expressed 
than in parental cells. Only SK Mel 28 res cells show an increased expression of p21. 
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5 Discussion 
Melanoma is one of the most aggressive types of skin cancer leading to the majority of 
skin cancer-related deaths. Targeted therapies are initially a very effective treatment but 
resistance occurs (Manzano et al. 2016). Therefore, understanding the mechanisms of 
resistance became the major topic of my study.  
In the present work I show that i) SOX2 and CD24 were upregulated upon short-term 
BRAFi treatment of melanoma cells and a similar upregulation was observed in iPCCs 
that are resistant to targeted therapy; ii) there was a positive correlation between SOX2 
and CD24 expression  based on the analysis of IHC stainings of tissue sections of 
metastatic melanoma specimens; iii) SOX2 could directly bind and activate the CD24 
promoter as revealed in luciferase reporter assays; iv) overexpression of SOX2 led to an 
increase in resistance towards BRAFi treatment which was attenuated by CD24 KD; v) 
CD24 overexpression could mimic the effect of SOX2 overexpression; vi) SOX2 KD 
resulted in a similarly decreased resistance towards BRAFis; vii) SOX2 OE and CD24 
OE activated STAT3 and Src, viii) Inhibition of Src or STAT3 could overcome the 
resistance mediated by SOX2 OE or CD24 OE ;ix) STAT3 was activated by soluble 
factors and activated STAT3 was required for the induction of SOX2 expression forming 
a feedback loop. The mechanism found in this study is summarized in Figure 24 
demonstrating that the activation of STAT3 by a soluble factor cleaved by sheddases 
promotes the expression of SOX2. SOX2 then binds to the CD24 promoter resulting in 
an upregulation of CD24 leading to an increased activity of Scr and STAT3. This 
mechanism helps tumor cells to circumvent the action of BRAF inhibitors. 
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Figure 24: Schematic overview of the SOX2 and CD24-mediated adaptive resistance. The treatment 
with BRAFi leads to an activation of NF-kappa B and sheddases. This leads to a secretion of soluble 
factors. These factors induce STAT3 activity that induces a higher expression of SOX2. SOX2 promotes 
the expression of CD24 by binding to its promotor. The increased CD24 expression causes a higher Src 
and STAT3 activation contributing to cell survival. STAT3 might provide an autocrine stimulus for further 
SOX2 expression. 
5.1 SOX2 and CD24 in adaptive resistance   
Here, I show that the expression of SOX2 and CD24 was increased in iPCCs which are 
resistant to targeted therapy (Bernhardt et al., 2017) as well as in short-time inhibitor 
treated melanoma cells (Figure 8 and Figure 9). Additionally, I could show that the 
melanoma cells treated with BRAFis as well as melanoma cells overexpressing SOX2 
reveal a more dedifferentiated phenotype (Figure 11). CD24 and SOX2 were already 
associated with a less differentiated and more cancer stem cell-like phenotype (Zhang 
2014; Lundberg et al. 2016; Yang et al. 2014; Santini et al. 2014; Ke et al. 2012) for 
which also a higher resistance towards therapy was shown (Fallahi‐Sichani et al. 2017). 
Interestingly, the later study by Fallahi‐Sichani et al. (2017) reported some new 
observations regarding the cellular response to vemurafenib in melanoma. It was 
observed on a single-cell level that the exposure of tumor cells to BRAFi caused a 
heterogeneous response in which some cells die, some arrest, and the remainders 
adapt to the drug. Drug-adapted cells upregulate neural crest markers (e.g., NGFR), a 
melanocyte precursor marker, and grow slowly.  
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This is in good agreement with the study of Sachindra et al. (2017) who showed a link 
between adaptive resistance and dedifferentiation in melanoma. Moreover, the study of 
Marzagalli et al. (2018) demonstrated that cells which survived treatment with 
vemurafenib formed more often spheres in comparison to control cells. These cells also 
showed an increased expression of stemness genes like SOX2. Therefore the authors 
claimed that these cells build the cancer stem cell population.  
Furthermore, both SOX2 and CD24 have also been linked to an increased therapy 
resistance (Song et al. 2016; Piva et al. 2014; Pietrobono et al. 2016; Deng et al. 2017; 
Surowiak et al. 2006; Ono et al. 2015; Jiao et al. 2013). This is in line with the data 
presented here that in melanoma cells an increased expression level of SOX2 or CD24 
resulted in a higher tolerance towards BRAFis (Figure 13A&B), while the depletion of 
SOX2 via KD led to higher sensitivity (Figure 15A-C). Similarly, the KD of CD24 in the 
more drug resistant SOX2 OE cells led to a restoration of sensitivity (Figure 15D). These 
findings indicate that SOX2 expression induced a higher resistance towards BRAFis via 
the upregulation of CD24, since overexpression of CD24 showed the same effect as 
SOX2 overexpression. Moreover, the data even reveal a direct regulation of CD24 by 
SOX2 as SOX2 is able to bind to the CD24 promotor activating CD24 expression (Figure 
12). Accordingly, in published CHIP-Seq data on the overexpression of SOX2 in human 
embryonic stem cells and human skin fibroblasts a binding of SOX2 to the CD24 
promotor at position -1342 in relation to the transcription start site can be found 
(Tsankov et al. 2015; Soufi et al. 2012; GEO acession number: GSM1505768; 
GSM896986). Hence, SOX2 regulated CD24 expression by a direct binding to its 
promotor. 
Additionally, to corroborate the SOX2 and CD24 expression data in clinical samples, I 
showed that both their expressions were correlated in metastatic melanoma patient 
samples (Figure 12C). As it is described that targeted therapy resistance can be due to 
selection of clones (Hong et al. 2017) I wanted to investigate if the increased expression 
of CD24 was due to selection of CD24-high clones or due to an increase in expression. 
Figure 10 shows that the increased expression of CD24 upon vemurafenib treatment 
was due to an upregulation of expression rather than selection. Previous work had 
demonstrated that CD24 has an influence on oncological properties such as cell 
proliferation and survival via an increased activity of Src and STAT3 (Baumann et al. 
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2012; Bretz et al. 2012). Therefore, I speculated that the upregulation of Src and STAT3 
activity might be the reason for the SOX2/ CD24-associated resistance. Indeed, I could 
show that a KD of CD24 resulted in a decreased activity of Src and STAT3 (Figure 15E) 
and CD24 overexpression activated Src and STAT3 (Figure 13D), confirming the study 
of Bretz et al. (2012) on malignant melanoma. Additionally, I could show that cells 
overexpressing SOX2 had a higher activity of Src and STAT3 (Figure 13C). These 
results are in good agreement with the study of Wang et al. showing that SOX2 
regulates the activity of Src in ovarian cancer (Wang et al. 2014). In addition, Figure 
14B&C shows that Src inhibition could hamper the SOX2/CD24-dependent resistance 
towards vemurafenib. This is consistent with recent studies showing that Src inhibition 
can overcome resistance (Girotti et al. 2015; Girotti et al. 2013). Moreover, Fallahi‐
Sichani et al. (2017) showed that drugs targeting the c-Jun/ECM/FAK/Src cascade can 
increase the maximum effect of BRAFi by promoting cell killing. Thus, the analysis at the 
single-cell level identifies signaling pathways and inhibitory drugs missed by assays that 
focus on cell populations.  
Additionally, I could demonstrate that the more resistant SOX2 or CD24 overexpressing 
cells were still sensitive to STAT3 inhibition (Figure 14E&F). This result is in good 
agreement with the study of Liu and colleagues (2013) showing that STAT3 inhibition 
can overcome targeted therapy resistance. Interestingly, the STAT3 inhibitor WP1066 is 
tested in a phase 1 clinical trial on patients with malignant glioma and brain metastasis 
from melanoma with an estimated completion in 2022.  
Furthermore, Lee et al. (2011) observed that CD24 drives tumor initiation via STAT3 and 
Wang et al. (2010) showed that CD24 can regulate the MAPK pathway, demonstrating 
the importance of CD24 in tumor cell survival and proliferation. Interestingly, I could also 
show that patients which survived longer had a lower CD24 expression compared to 
patients with a shorter survival time (Figure 15F). Hence, CD24 had a negative impact 
on survival. This is good agreement with several studies in different carcinomas 
summarized by Fang et al. (2010). In breast cancer, for instance; Kristiansen et al. 
(2003) could show that high CD24 expression correlates with poor prognosis and the 
same could be shown for cholangiocarcinoma (Agrawal et al. 2007). 
These findings suggest that SOX2 and CD24 play an important role in mediating 
adaptive resistance via upregulating Src and STAT3.  
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5.2 Are the CD24 mediated activation of Src and STAT3 interrelated?    
Bretz et al. (2012) have shown in carcinoma cells that CD24 KD impaired STAT3 
phosphorylation and similar results were obtained when Src was depleted. The authors 
suggested that Src was the kinase linking CD24 to the activation of STAT3. Similar 
findings were presented by Niu et al. (2002) for malignant melanoma. In contrast, we did 
not observe any effect of the Src kinase inhibitors on the vemurafenib-mediated 
phosphorylation of STAT3 in our experiments (Figure 14D). Likewise, in SOX2 OE A375 
cells that showed strong STAT3 activation the Src inhibitor treatment did not alter this 
status (Figure 14A). Moreover, Src KD via siRNA had no effect on the STAT3 activation 
as demonstrated in Figure 17E. In addition, we could observe an upregulation of STAT3 
already after 6 h of vemurafenib treatment while Src needed a longer time to get 
activated (Figure 17D). Consequently, I conclude that in our melanoma cell line model 
Src is not the kinase driving activation of STAT3. A recent study on colorectal cancer 
has shown that Hsp90 can serve as a signal-transmitting link between CD24 and STAT3 
(Wang et al. 2016). Another study demonstrated that CD24 OE upregulates β-catenin 
expression (Lubeseder-martellato et al. 2016). Together with the studies of Anand et al. 
(2011) and Hao et al. (2006) who showed that β-catenin upregulates and activates 
STAT3 this reveals a potential STAT3 activation by CD24 via β-catenin. But more 
research is necessary to determine how CD24 activates STAT3 during vemurafenib 
treatment. 
5.3 STAT3 activation is required for vemurafenib-induced SOX2 and CD24 
expression 
Several studies have already shown that STAT3 activation plays an important role in 
drug resistance (Liu et al. 2013; Zhao et al. 2016; H. J. Lee et al. 2014) as well as in the 
CD24-mediated tumor initiation (Lee et al. 2011). 
I could show that early activation of STAT3 was required to obtain an increased 
expression of SOX2 and CD24 upon vemurafenib treatment (Figure 17A-C). 
Additionally, a KD of STAT3 with siRNA resulted in a decreased expression of SOX2 
and CD24 (Figure 17E) while Src KD had no effect on the expression of SOX2 and 
CD24. Therefore, the STAT3 activation must be upstream of SOX2 which then regulates 
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the CD24 expression. That STAT3 is able to initiate the expression of SOX2 by directly 
binding to its promotor was already shown in two studies (Foshay & Gallicano 2008; 
Pietrobono et al. 2016). Foshay and Gallicano (2008) could show this in neural 
precursor cells while Pietrobono et al. (2016) even could show the binding of STAT3 to 
the SOX2 promotor in melanoma cells. 
Taken together, these results suggest that the vemurafenib-induced expression of SOX2 
and CD24 was due to vemurafenib-mediated activation of STAT3. 
5.4 How is STAT3 activated upon vemurafenib treatment? 
Here I showed that STAT3 was not activated by Src as reported by others (Bretz et al. 
2012; Niu et al. 2002) but rather by soluble factors since the supernatant of 
vemurafenib-pulsed cells alone was able to activate STAT3 (Figure 18B). Haferkamp et 
al. (2013) could already show that vemurafenib induces senescence in melanoma cells. 
In combination with the observation of Ohanna et al. (2013) showing that the secretome, 
especially CCL2 and IL-6, of senescent melanoma cells drives basal melanoma cells 
towards a mesenchymal phenotype and activates the STAT3 pathway, STAT3 activation 
might be due to secreted factors. Moreover, Sos et al. (2014) could even show that 
vemurafenib-induced IL-6 secretion can lead to resistance via the activation of STAT3. 
To test this hypothesis in our settings, a cytokine array was performed which did not 
show a significant upregulation of any cytokine present on the array upon vemurafenib 
treatment. As CCL2 and IL-6 were part of the array I conclude that the vemurafenib-
induced STAT3 activation is not due to their secretion. Pietrobono et al. (2016) showed 
another possible mechanism of STAT3 activation in melanoma. They could demonstrate 
that gentian violet (GV), a cationic triphenylmethane, can repress melanoma stem cell 
self-renewal through inhibition of SOX2. The authors suggested that GV suppressed 
STAT3 activation through an EGFR-dependent mechanism. Hence, EGFR activation by 
its ligands might be the reason for the vemurafenib-induced STAT3 activation. 
Therefore, a phospho-RTK array was performed (Figure 19). The most striking result 
was the activation of ErbB3. Interestingly, it was already shown that ErbB3 activation 
plays an important role in adaptive resistance (Abel et al. 2013) and is connected to 
STAT3 activation (Yu et al. 2014). Moreover, it could be shown that ADAMs lead to the 
cleavage of ErbB3 ligands such as heregulin 1β (Kirkegaard et al. 2014; Finigan et al. 
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2011). Additionally, Capparelli et al. (2015) showed that fibroblast derived heregulin 1β 
promotes resistance via the activation of ErbB3. This is in good agreement with my 
observation showing that if TAPI-2, an inhibitor of ADAMs, is present in addition to 
vemurafenib, STAT3 was less activated and the vemurafenib induced expression of 
SOX2 and CD24 was less pronounced (Figure 18C). Thus, it can be concluded that 
vemurafenib might activate STAT3 by ligands binding ErbB3 i.e. heregulin 1β which are 
cleaved by ADAMs. Hence, vemurafenib might have an influence on the activity of 
ADAMs or their accessibility to their substrate molecule like heregulin 1β. Further 
research is necessary to investigate how vemurafenib regulates ADAMs cleavage of 
molecules and to find out which ligand activates ErbB3. Moreover, it has to be proven in 
our system that ErbB3 is responsible for the vemurafenib-induced activation of STAT3. 
Another interesting finding is the early activation of NF-kappa B after vemurafenib 
treatment (Figure 18A). This is in line with the observation of Lehraiki et al. (2015) who 
could show that vemurafenib induces the activation of NF-kappa B promoting melanoma 
cell survival and vemurafenib resistance. While Lehraiki and collegues (2015) showed 
that the vemurafenib-induced activation of NF-kappa B is mediated by TNFα, which is 
highly secreted after administration of vemurafenib, I did not observe any change in the 
amount of TNFα in the supernatant after vemurafenib treatment. Moreover, TNFα 
treatment of cells did not change STAT3 activation or SOX2/CD24 expression (Figure 
18C). Hence, my results do not confirm the results by Lehraiki et al. (2015). However, 
there are other publications which also show that NF-kappa B activation is an important 
event/ prerequisite for STAT3 activation (Bretz et al. 2013; Agarwal & Zambidis 2014). 
Moreover, Hinohara et al. (2012) even showed that in mammosphere formation NF-
kappa B activation plays an very important role as it promotes ErbB3 activation via 
heregulin. Thus, it might be possible that the vemurafenib-induced NF-kappa B 
activation could lead to an ErbB3 activation via heregulin resulting in a STAT3 activation. 
As heregulin needs to be cleaved from the cell surface via ADAMs this would also 
explain the role of ADAMs in the vemurafenib-induced STAT3 activation.    
Thus, it is quite possible that diverse signaling pathways can lead to STAT3 activation 
which in turn can trigger SOX2 expression. It is becoming clear that feedback activation 
of STAT3 plays a prominent role in mediating drug resistance to a broad spectrum of 
targeted cancer therapies and chemotherapies including melanoma therapy.  
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5.5 The role of SOX2 and CD24 in acquired resistance in melanoma 
To examine if SOX2 and CD24 also play a role in acquired resistance, resistant cell lines 
were established (Figure 20). Apparently neither SOX2 nor CD24 played a major role in 
acquired resistance as in the established resistant cell lines HT144 res, A375 res and 
SK Mel 28 res SOX2 and CD24 expression were not permanently upregulated and 
vemurafenib exposure could not upregulate SOX2 or CD24 anymore (Figure 21A-
E&H&I). Moreover, a siRNA-mediated KD of SOX2 in cells that acquired resistance did 
not lead to a retrieval of sensitivity (Figure 21F&G). These observations are in 
agreement with a recent publication demonstrating that SOX2 has no oncogenic function 
during melanoma development and is not required for the acquisition of resistance to 
BRAFi treatments (Cesarini et al. 2017). 
Therefore, I conclude that SOX2-mediated upregulation of CD24 and the activation of 
Src and STAT3 are only instrumental in establishing resistance shortly after the start of 
vemurafenib treatment. It most likely acts as an emergency plan to rescue many cancer 
cells from death induced by BRAFi treatment.  
5.6 Melanoma cell lines with acquired resistance 
To further characterize the resistant cell lines, several signaling pathways were 
investigated. ERK phosphorylation was strong in all resistant cell lines, although they 
were still treated with the MAPK pathway inhibitors (vemurafenib or trametinib) (Figure 
22A). This finding is consistent with other studies showing that ERK is more strongly 
phosphorylated in resistant cell lines even if they are treated with MAPK pathway 
inhibitors (Herreros-Villanueva et al. 2013; Ahn et al. 2015). As increased activation of 
AKT is a possible mechanism promoting acquired resistance (Perna et al. 2015; 
Villanueva et al. 2011; Manzano et al. 2016), AKT activation in resistant cell lines in 
comparison to their parental counterparts was examined. Indeed, HT144 res and in SK 
Mel 28 res cells showed an increased activation of AKT (Figure 22A). Since I could 
show that Src and STAT3 signaling play an important role in adaptive resistance, I 
studied if their activation was changed in cells that acquired resistance. Interestingly, I 
found Src to be upregulated in HT144 res cells while STAT3 was upregulated in A375 
res 5 µM vem, A375 res 130 nM tra and SK Mel 28 res cells (Figure 22A). That Src and 
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STAT3 activity also play an important role in acquired resistance was shown by several 
studies (Sinnberg et al. 2011; Liu et al. 2013; Girotti et al. 2013; Girotti et al. 2015).  
The expression levels of MITF and Axl were shown to play an important role in 
conferring resistance to melanoma cells in several studies. The study of Müller et al. 
(2014) showed a relationship between early resistance and a low MITF/Axl ratio. Here, 
an elevated amount of Axl was only detected in SK Mel 28 res cells in comparison to the 
parental cells. These cells also showed a decreased expression of MITF (Figure 22B, C, 
E). Thus, these results are in good agreement with the study of Müller et al. (2014). 
Furthermore, a lower expression of MITF was detected in all resistant cell lines in 
comparison to their parental counterparts (Figure 22C&E). This is consistent with the 
findings from a great number of studies (Konieczkowski et al. 2014; Müller et al. 2014; 
Sun et al. 2014). Interestingly, some other studies reported the opposite, demonstrating 
that a high expression of MITF favors resistance (Van Allen et al. 2014; Johannessen et 
al. 2013). These discrepancies might be due to the different approaches used in the 
studies. Moreover, the majority of the resistant cells show a decrease in the expression 
of SOX10 (Figure 22D&E). This is in good agreement with the study of Sun et al. (2014) 
that demonstrated a loss of SOX10 in samples from patients that did not respond to 
targeted therapy. Another study revealed an increased expression of shRNA targeting 
SOX10 mRNA in resistant cells. Since SOX10 is important for differentiation in 
melanocytes less SOX10 leads to a more dedifferentiated and slower growing 
phenotype. This phenotype is associate with an increased resistance (Zhang & Herlyn 
2014). This is in line with my observation that in the majority of the resistant cell lines the 
CDK inhibitors p27 and p21 were increased favoring a less proliferative phenotype 
(Figure 23). Carlino et al. (2014) also showed that p27 is accumulated upon BRAF and 
MEK inhibitor resistance. Moreover, resistance to targeted therapy was also linked to an 
increased expression of EGFR (Sun et al. 2014; Zhang & Herlyn 2014). However, no 
increase in the EGFR expression in resistant cells was observed in this study (Figure 
22F). Further analysis of the microarray expression data revealed an altered activation 
of TGFβ signaling in the resistant cells. This is consistent with previous studies (Sun et 
al. 2014; Zhang & Herlyn 2014) showing that an altered TGFβ signaling plays an 
important role in resistance. Moreover, the microarray data also showed a change in cell 
survival, proliferation and cellular motility. These all are important feature in resistance. 
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Interestingly, I saw a downregulation of the tumor suppressor RUNX3 in the microarray 
data of resistant cells. RUNX3 downregulation was already shown previously to play a 
role in resistance (Zheng et al. 2013). AGPAT9, which I also found to be downregulated 
in the resistant cells, was already shown to be an important tumor suppressor and 
downregulated upon drug resistance in breast cancer (Fan et al. 2015). In contrast 
NUPR1 which has already been shown to induce resistance in different cancers is 
upregulated in resistant cells (Chowdhury et al. 2009). Taken together, these results 
suggest that the development of acquired resistance is accompanied by a broad 
spectrum of pathway alterations as well as changes in the expression of different 
proteins.  
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6 Conclusion 
 
Taken together, this work contributes to the understanding of the various steps involved 
in the development of vemurafenib-resistance, especially the adaptive resistance. Here, 
I report that BRAFi treatment led to an increase in STAT3 activation shortly after 
treatment with vemurafenib. This might be mediated by an increased shedding of for 
example heregulin 1β which then could bind to specific receptors (i.e. ErbB3) which are 
able to activate STAT3. The increased activation of STAT3 promoted SOX2 expression. 
SOX2 in turn upregulated the expression of CD24 by binding to its promotor. CD24 
activated Src and STAT3 signaling leading to increased cell survival. In accordance with 
this I showed that SOX2 or CD24 overexpressing cells can tolerate a higher dose of 
BRAFi treatment. Since inhibition of STAT3 or Src was still effective in the more 
resistant SOX2 and CD24 overexpressing cell lines, it might be beneficial to use Src or 
STAT3 inhibitors together with MAPK pathway inhibitors in order to block this escape 
pathway and thereby prevent adaptive resistance in clinical settings. Another possibility 
is to target CD24 directly by the use of monoclonal antibodies. Due to its high 
importance for different cellular functions targeting SOX2 might lead to a lot of unwanted 
side effects. 
While in adaptive resistance SOX2 and CD24 played an important role they seemed to 
be of minor impact in acquired resistance. Hence, other molecules and pathways which 
are yet to identify play a key role in acquired resistance. 
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Appendix 
 
 
Figure 25: Representative viability curves of cells that acquired resistance. A: A375, A375 res 7 µM 
vem and A375 res 5 µM vem cells treated with various concentrations of vemurafenib as indicated. B: 
A375 in comparison to A375 res 130 nM tra treated with different concentrations of trametinib as 
indicated. C: Viability curves of HT144 and HT144 res 2.5 µM vem treated with various concentrations of 
vemurafenib. D: Viability curves of SK Mel 28 cells in comparison to SK Mel 28 res 2µM vem treated with 
different vemurafenib concentrations.   
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Figure 26: Representative viability curves. A: Viability curves for A375 and SK Mel 28 EV and SOX2 
OE cells treated with different concentrations of vemurafenib are shown as indicated. B: A375 scramble 
control and SOX2 KD cells treated with different concentrations of vemurafenib to obtain a viability curve. 
C: KD of SOX2 made HT144 cells more sensitive as revealed by treatment with various concentrations of 
vemurafenib.  D: Viability curves of SK Mel 28 scramble control and SOX2 KD cells treated with various 
concentrations of vemurafenib, plx8394 and plx7904. E: A375 EV and CD24 OE cells treated with 
vemurafenib, plx8394 and plx7904. F: A375 SOX2 OE and CD24 OE cells treated with different 
concentrations of vemurafenib and DMSO (grey curve) or PP2 [50 µM] (black curve) in addition. G: A375 
cells with SOX2 or CD24 OE were treated with different concentrations of vemurafenib and DMSO (grey 
curve) or BP-1-102 [13.5 µM] (black curve) in addition. H: Viability curves of A375 SOX2 OE cells with 
siGFP (as control) or siCD24 knockdown treated with vemurafenib, plx8394, plx7904. 
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